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Chapter 1: Chemotherapy-induced Peripheral Neuropathy 
Abstract 
Peripheral neurotoxicity is an important side-effect of several 
chemotherapeutic agents. These agents may cause a usually axonal 
neuropathy, which may ultimately lead to severe and disabling symptoms 
and signs. Besides describing in this review the pathogenesis, the clinical 
presentation, the neurophysiological findings and the nerve biopsies, we also 
recount the relation between cumulative dosage/dosage per cycle and 
neuropathy for the cytostatic drugs for which neurotoxicity is an important 
side-effect: cisplatin, vincristine, paclitaxel, docetaxel and suramin. With the 
development of strategies to circumvent toxicities of other organs and \vith 
the use of combinations of neurotoxic agents such as cisplatinlpaclitaxel, 
neurotoxicity is an important and dose limiting side-effect of many treatment 
regimens. Detailed knowledge of the neurologic side-effects of these drugs is 
essential for the management of their neurotoxicity. The review concludes 
with a short discussion of neuro-protective agents. Although several nerve 
growth factors, gluthation and ethiofos hold promise as possible 
neuroprotective factors, the clinical data on these drugs are still limited. New 
trials are needed to confirm the value of these drugs. If neurotoxicity can 
indeed be prevented or delayed, this may lead to more effective treatment 
regimens. 
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Introduction 
Some of the chemotherapeutic agents are notorious for their toxic effects 
on the peripheral nerves. The severity of this complication may range from 
some loss of sensory function and mild paresthesias to neuropathic pain, 
severe ataxia and weakness leading to pronounced disability. The 
involvement of autonomic nerve fibres with orthostatic hypotension, 
impotence and incontinence may further reduce the quality of life. Many 
cytostatic agents have occasionally been reported to be neurotoxic, but in 
only a few drugs peripheral neuropathy is an important and dose limiting 
side-effect. The neurotoxicity of the older agents vincristine and cisplatin is 
well-known. In several of the newer and promising chemotherapeutic agents, 
Le. paclitaxel (Taxol@), docetaxel (Taxotere®) and suramin, neuropathy is 
also a prominent side-effect. Due to their neurotoxicity treatment with these 
drugs must often be discontinued, which may prohibit an effective treatment. 
In all these drugs, either the dose per cycle, or the cumulative dose, or the 
dose-intensity determines the severity of the neurotoxicity. If it were possible 
to prevent and/or modify the neurotoxic side-effects of these drugs, this 
would have important consequences for the efficacy of the treatment and the 
quality of life of these patients. A modification of dosing-schedules may be 
one possibility to prevent severe neurotoxicity. Others have tried to prevent 
chemotherapy-induced neuropathy with possible neuroprotective agents, 
some of which experiments showed promising results. This article reviews 
the drugs in which peripheral neurotoxicity is an important side-effect, and 
briefly discusses the possible role of (neuro)protective agents. As the taxanes 
are a new and important class of chemotherapeutic agents, some emphasis is 
put on these drugs. 
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Cisplatin 
Cisplatin is an effective cytotoxic agent in various malignancies, particula-
rly ovarian, testicular and bladder cancer. The anti-tumor effect is based 
mainly on the reaction with DNA, forming both intra- and interstrand 
crosslinks. Nephrotoxicity used to be the principal side-effect, but since the 
reduction of renal toxicity (by several measures such as a hydration 
schedule) and of gastro-intestinal side-effects neurotoxicity is regarded as a 
dose-limiting side-effect of cisplatin '. As in vitro studies on human cancer-
cell lines and clinical trials show a steep dose-response relationship for 
cisplatin, more intensive dosing schedules of cisplatin have been used ". 
Neurotoxicity was a major toxicity in many studies on high-dose cisplatin )'''. 
Infrequently, other neurotoxic effects have been reported: autonomic 
neuropathy '.ll.l3, optic neuropathy 14 and encephalopathic symptoms 
including cortical blindness and seizures 15.". 
Thus, in most cases neurotoxicity is limited to an axonal sensory 
neuronopathy and to ototoxicity. Ototoxicity mainly affects hearing in the 
high frequency range, the clinical spectrum of which varies between tinnitus 
and severe deafness ". The sensOlY neuropathy is due to damage of large 
myelinated Ia fibres, presumably at the level of the cell bodies of the sensory 
nerves located in the dorsal root ganglia "'''. Dorsal root ganglia are not 
protected by a blood-brain barrier, explaining a lO-fold higher cisplatin 
concentration at that site as compared to the brain and spinal cord ". 
Probably cisplatin binds or crosslinks proteins involved in microtubular 
structure and axonal transport ". 
The first symptoms of cisplatin neuropathy are paresthesias and 
numbness in a stocking and glove distribution, loss of tendon reflexes and a 
decrease in mainly thick fibre mediated sensory qualities such as vibration 
perception, fine touch perception and proprioception. This can lead to 
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difficulties in small motor coordination, As the neuropathy increases a 
disabling sensOlY ataxia may ensue, Muscle weakness is extremely rare 20","", 
Pain is not a symptom of cisplatin neuropathy, Some patients develop 
Lhermitte's sign or experience paresthesias and an electric shock sensation on 
stretching the arms or legs 27-32, The neuropathy may continue to deteriorate 
up to three to four months after cessation of therapy, This phenomenon 
probably reflects a time-lag in clinical manifestations of neuronal injUry 
related to ongoing pathological changes in axonal transport 6,8,33,,,, Thereafter 
a gradual but often incomplete recovery is the rule, leaving especially those 
patients with severe neuropathy with residual deficits 5,8,17,35,", 
Typically, nerve conduction studies (NCV) show a decrease or absense of 
sensory nerve action potentials, delayed sensory nerve conduction velocities 
and prolonged or absent H-reflexes, The motor nerve conduction and 
electromyography (EMG) are usually normal 11,>0""",29,37,", Sural nerve biopsies 
show a degeneration of large myelinated axons with signs of segmental 
demyelination and remyelination 70", 
The main prognostic factor for the severity of neuropathy is the 
cumulative dose of cisplatin I1,H,,,,40, With conventional doses of cisplatin 50-
75 mg/m' per cycle and cumulative doses exceeding 300 mg/m', the reported 
incidence of neuropathy varies between 24% and 92% 5,H,29,32,41,,,, In a large 
prospective Dutch study in which patients received a median cumulative 
dose of cisplatin between 500 and 600 mg/m', the overall incidence of any 
grade of neuropathy was 47%", The incidence in long survivors was even 
higher (61%), Severe neurotoxicity leading to walking difficulties occurred in 
4% of patients, Some authors have reported a relation between severity of 
neuropathy and age, gender or tumor type 3.43, 
In some studies cisplatin-toxicity was reduced by modifying the dosing 
schedule, Decrease of cisplatin dose-intensities by dividing the total dose over 
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several days is associated with less ototoxicity", gastrointestinal toxicity and 
nephrotoxicity". Other studies reported that a schedule with administration 
of cisplatin on day 1 and 8 was less toxic than the same total dose given over 
five days, so perhaps the accumulation of cisplatin is smaller when larger 
time intervals are used 46.47. It is unclear if the severity of neuropathy is 
influenced by alterations in the dosing schedule. In a comparative study we 
found only the cumulative dosage and not the dose-intensity to be related to 
the development of neurotoxicity". In contrast, in two other studies higher 
dose-intensities of cisplatin gave rise to increased neurotoxicity 5.11. A 
subsequent study in our institute on retreatment with cisplatin in patients 
with recurrent ovarian cancer following earlier treatment with cisplatin gives 
support for the importance of the dose-intensity. No significant neurotoxicity 
was observed despite the administration of a total cumulative dosage over 
800 nl ,. • 18 m5' m m most patients . 
Vincristine 
The vinca alkaloids are widely used in cancer therapy for both solid 
tumors and hematologic malignancies. These drugs bind microtubule 
associated proteins preventing the formation of micro tubuli in the mitotic 
spindle, thereby interfering with cell division. Microtubules are also involved 
in axoplasmatic transport and much of the neurotoxicity is explained by 
disruption of this process 35.49,50. 
Vincristine is the most frequently used vinca alkaloid due to its efficacy 
and relative lack of myelosuppression. However, it is also more neurotoxic 
than the other two, and this is the dose-limiting side-effect 35,50. Vincristine 
neuropathy is of a mixed sensory-motor and autonomic nature. Rare 
manifestations of vincristine neurotoxicity are cranial nerve involvement 51,53, 
seizures, mental changes and confusion, and the syndrome of inappropriate 
7 
Chapter 1: ClJelllotherapy-i"duced Peripheral Neuropathy 
antidiuretic hormone secretion ". Paresthesias involving hands and feet are 
an early manifestation, often occurring within the first few weeks of therapy. 
Many patients complain about numbness but usually the sensory symptoms 
outweigh the objective senSOIY deficits. The earliest and most consistent 
finding of vincristine neuropathy is the suppression of the achilles-tendon 
reflexes. Later on other deep tendon reflexes also disappear '1.52.54.55. Objective 
sensory loss is seldom severe. The neuropathy is painless, although severe 
pain in the region of the jaw or throat occasionally occurs after the first or 
second dose of vincristine ". Motor involvement is the most severe 
manifestation of neuropathy. It is often heralded by clumsiness· of the hands 
and cramps in the legs, and may result in severe weakness. The distribution 
of weakness is unusual, characteristically the weakness impairs the extensors 
of the fingers and wrist and the dorsi flexors of the toes and ankle 51.52.". 
Autonomic neuropathy is another frequent and early side-effect of vincristine 
".50. Often, this causes gastro-intestinal symptoms, \vith constipation, 
abdominal pain and paralytic ileus as the major manifestations '1.52.". Other 
less frequent manifestations of autonomic dysfunction include bladder atony 
with urinary retention, impotence and orthostatic hypotension 'I. Usually, 
recovery starts when the drug is withdrawn although symptoms and signs 
may first worsen to some extent. Even paresis is generally completely or 
partially reversible but recovery is often slow, requiring months. Sensory 
symptoms and hyporeflexia may persist but are not troublesome in most 
. " patIents . 
NCV studies show normal or near-normal sensOlY and motor nerve 
conduction velocities, with a reduction in the amplitude of the sensory nerve 
action potentials and compound motor potential. The EMG may show signs 
of denervation >4.". The H-reflex may be unimpaired despite the absence of 
achilles tendon reflexes. Guiheneuc et al. found a decrease of the ratio of the 
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amplitudes of the soleus muscle elicited by the achilles tendon reflex and the 
I-I-response the most sensitive early parameter ". These findings are 
compatible with an axonal degeneration of the 'dying back type'. The axonal 
nature of this neuropathy has been confirmed by nerve biopsies 50.58.60. 
The incidence and severity of vincristine neuropathy are related to both 
the single and cumulative dose. Treatment ,vithin a dose range of 2-6 mg/m' 
per month causes usually no more than mild paresthesias and reflex 
depression. Vincristine is predominantly excreted via the biliary system, 
therefore liver impairment increases the susceptibility to neurotoxicity". 
Concurrent neurotoxic medication may worsen the neuropathy. A pre-
existing neuropathy may make patients more susceptible to vincristine 
neurotoxicity. Severe neuropathy in patients with (asymptomatic) Charcot-
Marie-Tooth disease 61.62 and Guillain-Barre syndrome 6l has been reported. As 
stated, the other vinca-alkaloids like vinorelbine are less neurotoxic, due to 
their low affinity for axonal tubulin. Still, in one-third of paclitaxel pretreated 
patients vinorelbine caused a severe axonal sensori-motor neuropathy". 
Whether this was due to the pre-existent neuropathy or to a synergistic toxic 
effect remains unknown. 
Paclitaxel (Taxol®) 
Paclitaxel (Taxol®) is the first of a new important class of anti-cancer 
agents, the taxanes. Paclitaxel was discovered in 1963 as part of a large scale 
program of the National Cancer Institute (USA) to screen plant extracts for 
cytotoxic activity. A crude extract from the bark of the Pacific yew Taxus 
brevifolia, a slow-growing and scarce American evergreen, was found to have 
cytotoxic activity against a broad range of tumors 65.66. Clinical anti-tumor 
activity has been demonstrated against a variety of tumors 66. In contrast to 
other anti-microtubule drugs such as vinca-alkaloids that induce the 
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disassembly of microtubules, paclitaxel promotes the polymerization of 
tubulin forming very stable and dysfunctional micro tubules. It thus interferes 
with microtubule functions required for cell division and several vital 
interphase functions including maintenance of shape and intracellular 
transport 65~7. The main side-effects of paclitaxel are hypersensitivity 
reactions, myelosuppression, cardiac disturbances and neurotoxicity 65-". As 
myelosuppression can in part be circumvented with granulocyte colony-
stimulating factor (G-CSF), neurotoxicity is a dose-limiting side-effect 63,69. 
Paclitaxel induced neuropathy is probably due to dysfunctional micro tubuli 
in dorsal root ganglia, axons and Schwann cells 70.71. The primary site of 
pathogenesis is not clear. The distal symmetric length-dependent 
neurological deficits in some patients suggest a dying-back neuropathy, 
which may have its origin both in the cell body and in the axonal transport. 
On the other hand, the simultaneous onset of symptoms in arms and legs in 
some patients, and the occasional trigeminal involvement are also compatible 
with a neuronopathy. 
Autonomic neuropathic manifestations such as a paralytic ileus and 
symptomatic orthostatic hypotension have been observed but they are rare n. 
Other rare neurotoxicities include optic nerve disturbances 73, epileptic 
seizures n and encephalopathy H. The most frequent neurotoxic side-effect is 
a predominantly sensory neuropathy. Typically, signs and symptoms start 
shortly after the administration of paclitaxel and tend to improve before the 
next cycle ". Initial symptoms include numbness, paresthesias and a burning 
pain in a glove-and-stocking distribution. There is often a simultaneous onset 
in hands and feet, sometimes with facial involvement 70. At examination distal 
loss of both large and small fibre mediated sensory qualities and loss of deep 
tendon reflexes can be found. In patients with more severe neuropathy motor 
involvement is not rare, usually as a mild distal weakness, but some patients 
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go on to develop a severe weakness 76,77, The neuropathy may be extremely 
painful or accompanied by disabling dysesthesias, Some patients have 
transient myalgias 2-3 days after the administration of taxol, which resolve in 
a few days ", A myopathy has been described in patients with high doses of 
paclitaxel 000-350 mg/m2) in combination with cisplatin 79, In most patients 
the neuropathy improves after the end of treatment, but progressive 
detoriation of the neuropathy with severe weakness following the 
discontinuation of treatment has been described 76,80, 
Nerve conduction studies usually show a predominantly axonal sensory, 
but in more severe cases both axonal degeneration and demyelination may be 
present with widespread denervation signs and severe conduction 
abnormalities, Sural nerve biopsies showed mainly axonal loss 10,16,81, 
The severity of neuropathy is related to both the single and cumulative 
dose of paclitaxeL At lower dosages per cycle(135-200 mg/m2) neuropathy is 
rare, occurring at a higher cumulative dosage (>1400 mg/m2) and usually 
mild ", At a higher dosage per cycle (>250 mg/m2) a more severe neuropathy 
is frequent, which often starts in the days following the first cycle 10,,,, Despite 
the frequent improvement before the next cycle, with more cycles the 
symptoms increase "''', It has been suggested that the neuropathy may be 
more severe if paclitaxel is administered in three hours as compared to 24 
hours, due to a higher area under the concentration-time-curve 82, Other risk 
factors include prior exposure to other neurotoxic agents and antecedent 
medical disorders (alcoholism, diabetes mellitus) associated with peripheral 
neuropathy 77, Especially in diabetes mellitus severe neuropathies have been 
described 80,83, Amitryptiline may be useful to treat neuropathic pain in 
taxanes-induced neuropathy, 
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Docetaxel (Taxotere ®) 
Because the natural supply of the source of paclitaxel is limited, a 
synthetic pathway was sought. In 1986 this resulted in a semi-synthetic 
taxane, docetaxel (Taxotere ®) for which a precursor extracted from a 
renewable source, the needles of the European yew (Taxus baccata), was 
used ", Structurally, docetaxel is closely related to paclitaxel and has the 
same mechanism of action: it inhibits tubulin depolymerization and 
promotes microtubule assembly, thereby stabilizing microtubules, In vitro 
docetaxel is twice as potent as paclitaxel ", In recent years docetaxel has been 
found to be one of the most active new anti-neoplastic agents, Phase I and II 
trials have shown significant clinical activity in ovarian cancer, breast cancer, 
melanoma, non-small-cell lung cancer and small-cell lung cancer ", Neutro-
penia is the dose-limiting toxicity in most studies, Other side-effects are 
hypersensitivity reactions, a fluid retention syndrome ,vith peripheral edema, 
gastro-intestinal toxicity, cutaneous toxicity, onchylysis and a peripheral 
sensory neuropathy", The precise mechanism of docetaxel-induced 
neuropathy is unknown, but based on the resemblance with paclitaxel it may 
also be due to the formation of dysfunctional micro tubules, 
In phase II trials of docetaxel treatment with a dose of 100 mg/m' every 3 
weeks, after 3 or 4 cycles 37%-54% of the patients developed a usually mild 
but occasionally severe dose dependent sensory neuropathy with numbness 
and paresthesias in a glove-and-stocking distribution 85~8, In a study con-
ducted in our institution 20 out of 41 evaluable patients treated with 
cumulative doses ranging 150-1100 mg/m' developed a usually mild 
neuropathy", However, of the 15 patients treated with a cumulative dose 
above 600 mg/m' 11 developed a neuropathy, which was considered modera-
te or severe in 4 89, Symptoms started with paresthesias and numbness in 
hands and feet and loss of tendon reflexes and vibratory perception were 
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early signs. With the progression of the neuropathy the paresthesias became 
disabling or painful, suggesting involvement of small unmyelinated nerve 
fibres. Due to the numbness with loss of joint position sense several patients 
developed loss of dexterity and unsteadiness of gait. Although signs and 
symptoms were dominated by a sensory neuropathy, in one patient severe 
weakness was observed 89.",. New et al. found evidence of motor weakness in 
half of the patients with docetaxel neuropathy 91. Another series reported a 
predominantly proximal weakness in 7 out of 60 docetaxel treated patients ". 
Similar to in cisplatin induced sensory neuropathy, Lhermitte's sign was 
observed 93. In most patients symptoms tend to improve following the 
discontinuation of the treatment, but in some patients the symptoms first 
increase to improve again after 4-8 weeks 89'91. N CV studies show a 
predominantly axonal sensory neuropathy, in more severe cases conduction 
abnormalities may be present and the EMG may show denervation signs """. 
In our experience the neuropathy is related to the cumulative dose, with 
more severe symptoms and signs in patients treated with a cumulative dosage 
over 600 mg/m2 • Liver function disturbances interfere with the metabolism of 
docetaxel, and they have been related to more severe side-effects ". This may 
also account for individual susceptibility for neurotoxicity as encountered in 
some patients "'. The dosage per cycle is also important, since we have 
observed an ameloriation of docetaxel neuropathy despite a continuation of 
treatment at a lower dosage (75 mg/m2 per cycle instead of 100 mg/m2) 93. 
Steroids reduce several side-effects of docetaxellike the fluid retention 
syndrome, but we observed no reduction of docetaxel induced neuropathy by 
steroid co-medication during treatment 95. 
13 
Chapter 1: Chemotherapy-induced Pelipheral Neuropathy 
Discontinuation of treatment in taxanes induced 
neuropathy 
Although infrequent, sometimes the only significant toxicity of taxanes is 
the neuropathy. Especially in a patient with a tumor response to the 
treatment this poses a difficult problem. On the one hand continuation of the 
treatment may result in a severe neuropathy, whereas discontinuation means 
the cessation of an effective drug. No studies have yet addressed this clinical 
issue. In general, symptoms and signs of taxane-induced neuropathy 
diminish once the treatment is discontinued but this is not always the case 
76.80.89-91. Some patients detoriate after discontinuation, and they may even 
develop severe weakness. Also, in occasional patients the residual symptoms 
have a great influence on the quality of life. In general, we discontinue the 
treatment once signs and symptoms interfere with daily functions such as 
tightening buttons and walking, or when patients develop motor signs. 
Invariably, NCV studies in patients treated with taxanes show an axonal 
sensory neuropathy. We also consider discontinuation of the treatment once 
NCV studies show an axonal motor neuropathy or significant motor 
conduction disturbances. It is unknown if treatment must always be 
discontinued, since we have observed the amelioration of docetaxel induced 
neuropathy following dosis reduction 93. 
Combination treatment with taxanes and cisplatin 
Cisplatin and taxanes act against the same tumors, like ovarian carcinoma 
and head/neck cancer. Taxanes have been effective in patients with platinum 
resistant tumors, and in ovarian cancer the combination of cisplatin and 
paclitaxel was found to be more effective than the standard treatment with 
cisplatinlendoxan go. As a result, many patients are now treated either with 
both drugs at the same time or in succession. Although by a different 
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mechanism, both drugs are neurotoxic and thus a cumulative neurotoxicity 
may be expected 97, Indeed, pre-treatment with cisplatin has been related to 
an increase in neurotoxicity of a subsequent treatment with either paclitaxel 
or docetaxel 93,99, Unfortunately, no well-designed studies have addressed this 
issue, and in studies on docetaxel neurotoxicity no evidence for increased 
neurotoxicity was apparent in cisplatin pre-treated patients 41,,,, In a large 
study on 1000 patients \vith platinum refractory ovarian cancer treated with 
135 mg/m' paclitaxel per cycle, only 2% of the patients developed a moderate 
or severe neuropathy 100, Thus, there is no reason to refrain from taxanes-
based chemotherapy in cisplatin pre-treated patients or vice versa, although it 
certainly justifies a more careful approach, 
As expected, a combination chemotherapy of taxanes and cisplatin 
induces a sensory neuropathy in a significant number of patients, In phase I 
trials on a combination chemotherapy of cisplatin and paclitaxel, sensory 
neuropathy was a dose limiting toxicity 68,80,101, The neuropathy seemed 
mainly due to the dose per cycle and cumulative dosage paclitaxel, 
Neuropathy was rare in patients receiving less than 200 mg/m' paclitaxel per 
cycle, but frequent in those treated with >200 mg/m' per cycle, This is no 
surprise, as at this dosage paclitaxel is neurotoxic by itself, A phase III trial 
on combined paclitaxeVcisplatin chemotherapy employing 135 mg/m' 
paclitaxel administered over 24 hours underscores this, since no increase in 
neurotoxicity was observed compared to the treatment with 
cisplatinJendoxan ", Conflicting results were reported on the treatment with 
cisplatin 75 mg/m' and paclitaxel135-175mg/m' administered over 3 hours, 
With this treatment, one study observed frequent neurotoxicity which was 
severe in one-fifth of the patients 102, In contrast, others observed no 
significant neurotoxicity, and comparison to a control group treated with 
cisplatin and cyclophosphamide showed similar neurotoxicity of the latter 
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regimen 103. In our experience, neurotoxicity is a dose limiting toxicity of this 
schedule. In a dose finding phase I study on docetaxeVcisplatin 
chemotherapy, we observed a neuropathy in 24 out of 35 patients treated 
with a cumulative dosage over 200 mg/m2 of both cisplatin and docetaxel. 
The neuropathy was considered moderate in 10, and severe in one patient. 
The combination appeared to be more neurotoxic than either drug alone at 
the same dosage level, thus these drugs may have a synergistic effect on 
neurotoxicity 104.105. It is often possible to decide which agent causes the 
neuropathic synlptoms, as the clinical picture (onset of symptoms, pain) is 
different between the two drugs. This may allow dose reduction. Even in 
patients with a severe neuropathy due to this combination chemotherapy, 
signs and symptoms are usually, at least partially, reversible. 
Suramin 
Suramin is a polysulfonated naphtylurea which has been used since the 
1920s as an antiparasite agent 106. Recently, suramin has received attention as 
a potential anti-neoplastic agent, because of its capacity to disrupt several 
systems important to tumor proliferation, in particular the inhibition of 
several cellular growth factors. In clinical trials the drug appeared to have 
clinical activity in prostate cancer 107.108, ovarian cancer iO'}, and non-Hodgkin 
lymphoma 107. The inhibition of growth factors by suramin, in particular the 
fibroblast growth factor and nerve growth factor, may playa role in the 
peripheral nerve damage. In in-vitro studies the high dose nerve growth 
factor was able to ameliorate suramin-induced dorsal root ganglia damage 110. 
Toxicities reported in these trials include myelosuppression, renal toxicity 
and adrenal insufficiency. Peripheral neuropathy was a main and dose-
limiting side-effect. Many patients developed a mild neuropathy (NCl-criteria 
: grade I and 11) with mainly sensory symptoms but with a higher dosage as 
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many as 11-23 % of patients developed a severe sensori-motor neuropathy. 
This toxicity was directly proportionally related to plasma suramin levels 
with a 40% probability of developing a severe neuropathy for those whose 
I I I I d d nl 1103.111 p asma pea < eve s excee e 350 Jl5' m . 
LaRocca reported in detail on the clinical, electrophysiological and 
histological features of severe suramin-induced sensori-motor neuropathy in 
four out of 38 suramin-treated patients 112. In two of these patients the clinical 
syndrome resembled that of a subacute Guillain-Barre syndrome with 
progression to complete flaccid paralysis with bulbar and ventilatory 
involvement. Two other patients developed a flaccid paresis of the limbs. All 
four patients demonstrated an elevated CSF protein in the acute phase of 
their neuropathy. The EMG and NCV showed evidence of conduction block, 
and sural nerve biopsies showed segmental demyelination. Recovery was 
complete in two, but the other two patients were left \vith severe residual 
weakness 112, 
Suramin-induced neuropathy appears to be a potentially serious toxicity 
that requires careful monitoring of plasma drug levels and cessation of 
treatment upon achieving plasma suramin concentrations of 300 Jlg/mlll2. 
Other chemotherapeutic agents 
Cytosine Arabinoside (Ara-C): This antimetabolite, used for the 
treatment of hematological malignancies, is associated with central nervous 
system toxicity. Peripheral neuropathy is a rare complication of Ara-C 
treatment. To date only a few cases have been reported lll. The clinical 
syndrome varied: a pure sensory neuropathy, a rapidly progressive ascending 
polyneuropathy with ventilatory dependency, a sensorimotor polyneuropathy 
and a bilateral brachial plexopathy have all been reported lll.lH. No clear 
correlation with the cumulative dose and the number of cycles seems present. 
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Procarbazine: This is a weak monoamine oxidase inhibitor used for the 
treatment of lymphomas, SCLC and primary brain tumors. A mild peripheral 
neuropathy has been reported in 10-20% of the patients, manifested by 
paresthesias, depressed deep tendon reflexes and myalgia 35.ll5. These 
symptoms tend to occur only after several weeks of continuous oral therapy 
and they are reversible after discontinuation of the drug. 
Ifosfamide: The neurological toxic effects of this cyclophosphamide 
analog mainly comprise central nervous system side-effects. Severe, short-
lasting exacerbation of a pre-existing mild peripheral neuropathy has been 
reported in four patients receiving high-dose intravenous ifosfamide. Patients 
developed a sudden onset of severe paresthesias and extreme pain in their 
hands and/or feet. The symptoms lasted for a few hours, then gradually 
improved over a few days and eventually returned to base-line over a few 
weeks. A rechallenge with ifosfamide led to the recurrence of the 
exacerbation 116. 
Neuroprotective agents 
Presently, no therapeutic options are available once a patient develops a 
chemotherapy induced neuropathy. One can only try to diminish symptoms 
with symptomatic treatment, such as amitryptiline in case of a painful 
taxanes induced neuropathy. The prevention of toxic neuropathies by 
administration of rescue-drugs would have great clinical significance, as this 
would also allow a more intense cytostatic treatment with agents in which 
neuropathy is a dose limiting toxicity I.B.II7.llS. A prerequisite for the use of 
any such drug is, that it does reduce antitumor activity of the cytostatic 
agent. Both neurotrophic factors (the ACTH analogue 4-9, insulin like 
growth factor and nerve growth factor) and sulfahydryl group containing 
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drugs (ethiofos or WR-2721 and glutathion) have been investigated for this 
purpose, Most of the research has been done in either in-vitro models or 
animal models, in which it was investigated whether a co-drug prevented or 
ameliorated the effect of the neurotoxic drug in the model. As in-vitro models 
cultures of embryonic rat dorsal root ganglia cells and schwann cells were 
often used, with outgrowth of neurites, cell survival or migration of cells as 
outcome parameters 23,119, In animal models, usually motor and sensory nerve 
conduction studies, tests for sensory pathways as the tail-flick test, and the 
determination of sensOlY neurotransmitters as substance P and calcitonine 
I d 'd d 71,120·124 0 I f gene re ate peptl e were use as outcome parameters ,n ya ew 
drugs have been tested in clinical trials (the ACTH analogue 4-9, ethiofos and 
glutation), 
As cisplatin has a steep dose-response curve, attempts have been made to 
deliver higher doses of cisplatin with the use of other drugs as a 
chemoprotective agent. The nUcleophilic sulfur containing compounds 
ethiofos or amifostine (WR272l) and reduced gluthathione have showed a 
selective protection of normal tissues in preclinical and clinical studies 
against the platinum compounds 1l7,m,l26, Amifostine is an organic 
thiophosphate that protects against cisplatin-induced nephrotoxicity, 
haematologic toxicity and neurotoxicity in animal models ,,1l7,llS, The drug 
probably accumulates more easily in normal cells than in tumor cells, and it 
rescues normal cells from cisplatin toxicity by binding to active cisplatin "', 
Clinical studies combining cisplatin and WR-2721 have revealed promising 
I 5,117.l27.129 Th I' f d' d 'I I resu ts ,e ana YSls 0 a ran onllse tna a so suggests a 
neuroprotective effect, but the small number of patients, the relatively low 
dose of cisplatin used (420 mg/m2) and the small number of patients \vith 
long-term follow-up hamper a meaningful analysis 126, Gluthathion was 
developed as a nephroprotectant, but in a clinical study it also seemed to 
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reduce neurotoxicity 125,130, Thereafter, it was found to reduce cisplatin 
induced neurotoxicity in rats 121, A randomised trial suggested this drug is 
indeed neuroprotective, but the duration of the follow-up was too short to 
observe the usual increase of cisplatin neuropathy following the end of the 
treatment 125, 
The observation that ACTH and the ACTH(4-9) analogue org 2766 can 
exert trophiC effects on neural tissue has led to several studiJ:s on the 
prevention of chemotherapy-induced polyneuropathy, In in-vitro models Org 
2766 was effective in modifying cisplatin neurotoxicity n,1l9, In a rat model 
Org 2766 prevented cisplatin-induced reduction of sensOlY nerve conduction 
velocities 131.133, In a subsequent placebo controlled study the treatment with 
Org 2766 indeed prevented the occurrence of cisplatin-neuropathy 134, Based 
on these studies, further trials in cisplatin neuropathy were performed but 
they either could not confirm these results or were less convincing ",m,136, As 
expected, we were also unable to demonstrate a beneficial effect of org 2766 
on cisplatin neuropathy of longstanding duration 137, Org 2766 has also been 
studied in vincristine and paclitaxel neuropathy, In a snail model, org 2766 
partially prevented the vincristine induced decrease of micro tubules 13S, A 
preliminary clinical study on vincristine neuropathy showed promising 
results 139, Although in in-vitro studies org 2766 seemed not effective in taxol 
induced neuropathy, in a rat model org 2766 prevented taxol induced SNCV 
slmving 119.140, Unfortunately, the lack of a clear benefit of Org 2766 in 
cisplatin induced neuropathy has led to a complete cessation of trials with 
Org 2766 in toxic neuropathies (Vecht, personal communication), 
Nerve growth factor (NGF) is necessary for the development of dorsal 
root ganglions and the maintenance of the normal ganglion function in adults 
122 
A neuroprotective effect of nerve growth factor was suggested by several in-
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vitro studies on cisplatin, paclitaxel and suramin neurotoxicity 23,110,141,14', In 
animal models, NGF prevented the taxol and cisplatin induced decrease of 
the compound motor action potential, and the increase of the threshold of 
thermally induced pain 71,122. Clinical trials have to be waited. 
The actions of the neurotrophin family members such as NGF are 
mediated by Trk tyrosine kinase receptors. Large dorsal root ganglions cells 
\vith myelinated axons involved in proprioception express the neurotropin-3 
receptor TrkC. These are the sensory neurons most affected by cisplatin. 
Neurotropin-3 was found to reverse cisplatin induced peripheral sensory 
neuropathy in rats IH. No clinical trials have yet been carried out. Insulin-like 
growth factor-l is a factor probably involved in regulating body growth 
during development. It has a variety of other actions, including a stimulation 
of motor and sensmy nerve regeneration. In animal experiments, it prevented 
the development of both vincristine and paclitaxel induced neuropathy 123.143 • 
It is currently being tested in clinical trials ,vith cisplatin and taxo!. 
In conclusion, in the past years a number of interesting possible 
neuroprotective drugs have been investigated, but the evidence obtained in 
clinical trials is still meagre. This holds for both the safety and the efficacy 
data. It is most important for such trials (especially those concerning 
cisplatin chemotherapy) that the follow-up period is long enough to observe 
the usual increase of neuropathic symptoms and signs in the period after the 
end of the treatment. Also, the value of observations obtained from studies 
employing a dosage causing none or only minor neuropathic symptoms in 
the majority of patients is unclear. 
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Abstract 
An intensive weekly regimen of cisplatin was administered to 66 patients 
with solid cancer in doses varying from 70-85 mg/m2 • The occurrence of 
sensory neuropathy was prospectively examined by the assessment of neuro-
pathic signs and symptoms and measurement of the Vibration Perception 
Threshold (VPT). The evaluation was performed before initiation of the 
therapy and during the follow-up until 3 to 12 months after the last cycle of 
cisplatin. A mild or moderate neuropathy developed in 47% of patients at 2 
weeks after the treatment. This neuropathy continued to deteriorate until 
approximately 3 months after cessation of chemotherapy leading to a mild or 
moderate neuropathy in 71 % of the patients and a severe neuropathy in 9% 
of the patients. Thereafter we observed a gradual but incomplete recovery. 
The high incidence of neuropathy we found may be explained by the 
prolonged observation period compared to earlier reports. 
The only factor correlating with the severity of the neuropathy was the 
cumulative dose of cisplatin, while there was no association with either the 
pre-treatment VPT, age, sex, tumor-type or co-treatment with etoposide. The 
progressing course up to approximately 3 months after the end of the 
treatment underscores the need for a prolonged follow-up in future studies 
on cisplatin neuropathy. 
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Introduction 
Cisplatin is a cytotoxic agent effective against a wide spectrum of solid 
tumors. Neuropathy is one of its dose-limiting side-effects. This neuropathy 
is purely sensOlY and characterised by paresthesias, the loss of tendon 
reflexes and a decrease of mainly thick-fiber mediated sensory qualities as 
vibration perception, fine-touch perception and propriocepsis. In some 
patients a disabling sensory ataxia may develop H. The reported incidence, 
time of onset and severity vary considerably between different studies, 
depending on the criteria for neuropathy, the extensiveness of the 
neurological examination and the cumulative dose of cisplatin administered 
A dose-response relationship for cisplatin has been shown in studies on 
human cancer-cell lines and has also been suggested by data from several 
clinical trials 5.8,12. Because potentially severe side-effects like nephrotoxicity 
and hyperemesis can now be reduced by vigorous hydration, the use of 
hypertonic saline and potent anti-emetics, more intensive dosing schedules of 
cisplatin have become feasible, leaving neurotoxicity as the dose-limiting 
factor. It is uncertain whether apart from the cumulative dose of cisplatin 
other factors determine the severity of neuropathy development. 
A large phase II study with an intensive weekly schedule of cisplatin for 
patients with locally advanced or metastatic solid tumors was performed in 
our institution. In these patients the incidence, severity and course of 
cisplatin-induced neuropathy were assessed prospectively. The size of the 
study enabled us to investigate the prognostic value of these factors on the 
severity of the neuropathy. The Vibration Perception Threshold (VPT) was 
used as the main quantitative measure of the severity of the neuropathy. 
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Patients and methods 
For this study, patieuts were required to have metastatic or locally 
advauced cancer for which no other appropriate therapy was available. Other 
inclusion criteria were age 18-75 years, WHO performance status of 0-2 and a 
life-expectancy of more than 3 months. Cisplatin was dissolved in NaCl 3% 
and administered in a 3-hour infusion with standard pre- and post-hydration. 
The administration took place in a weekly regimen of doses varying from 70-
85 mg/m2 • In some patients one week off-therapy was allowed after the third 
cycle. In most patients the cisplatin was combined with etoposide in a daily 
dose of 50 mg orally 2 or 3 weeks per month, which was continued after 
cessation of cisplatin with a dose of 50 mg/m2 daily at days 1 to 21 every 4 
weeks for a maximum of 4 cycles. All patients participating in this trial who 
had received at least 4 cycles of cisplatin were considered evaluable for the 
assessment of neurotoxicity. Excluded were patients with diabetes mellitus, 
alcohol abuse, earlier treatment with cisplatin and brain or leptomeningeal 
metastases. 
The severity of the neuropathy was evaluated by a questionnaire for 
neurological symptoms, by neurological examination and by VPT measu-
rements before the start of treatment, at 2 weeks after the last dose of 
cisplatin and every 3 months up to 12 months thereafter. The questionnaire 
established separately the absence (0) or presence (I) of paresthesias, 
numbness, loss of dexterity, unsteadiness of gait, Lhennitte's sign and pain. 
On sensory examination position sense, vibration sense, pin-prick sensation, 
Romberg's sign, Romberg's sign with heel-to-toe stand and tight-rope walking 
were each scored as normal (0) or abnormal (1). A sum-score for these signs 
and symptoms was calculated (minimum 0, maximum 12). Patients with a 
sum-score of 2 to 6 were considered to have a mild or moderate neuropathy 
and with a sum-score of 7 or more to have a severe one. The VPT was 
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measured at the dorsum of the second metacarpal bone of the left hand with 
a Vibrameter type III (Somedic AB, Stockholm, Sweden) and recorded in 
micrometers (/lm) of skin displacement. The Vibrameter uses a vibratory 
frequency of 100 Hz and corrects for pressure-induced alterations of 
vibratory amplitude. The method of limits was used to obtain the mean VPT 
and this was repeated three times. This method has been shown sensitive and 
reproducible ". The VPT has been shown to be a reliable technique to 
monitor cisplatin neuropathy and shows a satisfactory correlation with the 
sum-score of neuropathic signs and symptoms as observed previously Ii-17. 
The mean sum-score and mean VPT for the whole group pre-treatment 
and at several time-points post-treatment were calculated. The maximum 
sum-score post-treatment per patient was determined. Because of the skewed 
distribution of VPT, the natural logarithm was used for statistical analysis. 
The mean and standard deviation of the VPT are reported in original units, 
but were derived from the mean and standard deviation of 10g(VPT). By this 
procedure the means are less sensitive to outliers. Spearman rank correlation-
coefficients between clinical parameters and the VPT were calculated. 
Analysis of variance (ANOVA) was applied to study the relationship of the 
pre-treatment VPT with age, sex and tumor-type. Linear regression analysis 
was applied for comparison of several prognostic factors with maximum 
post-treatment VPT. 
Results 
Sixty-six patients were entered in the study. Patient characteristics and 
tumor type are shown in table 2.1. Three patients received 4 cycles, 6 patients 
5 cycles and 57 patients 6 cycles of weekly cisplatin. The cumulative dose of 
cisplatin was 420 mg/m' in 34 patients, less than 420 mg/m' (280-400 mg/m ') 
in 10 patients and more than 420 mg/m' (450-510 mg/m') in 22 patients. 
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Forty-three patients were co-treated with etoposide. All patients were 
examined before the start and at least once after cessation of the treatment. 
The length of the follow-up was 3 months for 19 patients (29%), 6 months 
for 18 patients (27%), 9 months for 18 patients (27%) and 1 year or more for 
11 patients (17%). 
Table 2.1 
patient characteristics and tumor type 
number of patients 
sex male/female 
age lnean years 
(range) 
tumor type 
head and neck 
pleural mesothelioma 
colorectal 
melanoma 
non-small cell lung 
other 
66 
51/15 
55 
(34-71) 
15 
13 
12 
9 
8 
9 
Before the start of the treatment 16 patients (24%) had a mild or moderate 
neuropathy (sum-score 2-6). Table 2.2 shows the maximum sum-score for 
signs and symptoms after the treatment. Forty-six patients (71%) had a mild 
to moderate neuropathy and 6 (9%) a severe one. Thirteen patients (20%) did 
not develop any neurotoxicity. 
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Table 2.2 
Severity of cisplatin neuropathy and maximal 
sum-score of signs and symptoms post-treatment 
neuropathy N" (%) lllaX.SUlll-score 
post-treatment 
no 13 (20%) 0 
1 
mild to 46 (71%) 2 
moderate 3 
4 
5 
6 
severe 6 (9%) 7 
8 
9 
10 
N 
8 
5 
12 
10 
8 
10 
6 
3 
1 
1 
1 
1} N indicates number of patients; data all 1 patient incomplete 
A significant correlation was found between the pre-treatment VPT and 
age (Spearman rank-correlation = 0.50; P = < 0.001). No correlation was 
observed between the pre-treatment VPT and gender or tumor-type. The VPT 
values correlated significantly with the sum-score for signs and symptoms 
measured at the same evaluation (Spearman rank-correlation = 0.56; P = < 
0.001). 
Regression analysis showed that the maximum post-treatment VPT 
correlated significantly with the cumulative dose of cisplatin (p = < 0.001) 
and the pre-treatment VPT (p = 0.003). Table 2.3 shows the pre-treatment 
VPT, the maximal post-treatment VPT and the relative increase of the VPT in 
relation to the cumulative dose of cisplatin. The post-treatment VPT was 
increased compared to the pre-treatment value in 63 of 66 patients (96%) 
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with an average increase of 222%. The relative increase of the VPT was 
exponentially higher in patients receiving higher cumulative doses of 
cisplatin. No difference in the maximal post-treatment VPT was found 
between patients co-treated either with or without etoposide. The pre-
treatment VPT of patients who developed a severe neuropathy did not differ 
from other pre-treatment values. 
Table 2.3 
pre-treatment VPT, maximal post-treatment VPT and relative 
increase of VPT in relation to cumulative dose of cisplatin 
cum. dose pre-treatment post-treatment relative increase I) 
cisplatin VPT max.VPT mean ±SD 
(mg/m2) N (%) mean ±SD mean ±SD 
< 420 10(15%) 0.7 ±0.8 1.5 ±1.2 105% ±780,6 
= 420 34(52%) 0.8 ±0.5 2.1 ±1.4 153% ±177% 
> 420 22(33%) 0.7 ±0.3 3.8 ±2.9 470% ±507% 
66(100%) 0.8 ±0.5 2.4 ±1.9 222% ±271% 
l)relative increase = 100x(postVPT - preVPT)/preVPT 
Figure 2.1 presents the mean VPT fitted against time by the cumulative-
dose group. It clearly shows that the magnitude of the post-treatment VPT 
value depends on the cumulative dose of cisplatin. It also shows that the 
maximal VPT values occur in the period around 3 months after the last 
cisplatin administration with subsequent improvement thereafter. 
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Figure 2.1 
Mean Vibration Perception Tilresilold (VPT) fitted against time by cIIlIllllative-dose grollp. 
Standard deviations of mean vallies at 3 months after tile last cycle of cisplatin. 
12m 
Table 2.4 expresses this course of neuropathy. It shows a similar pattern 
of increase in the frequency of paresthesias and other signs and symptoms 
and of the VPT scores achieving a maximum at around 3 months after the 
treatment and gradual but incomplete improvement thereafter. 
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Table 2.4 
Paresthesias, sum-score of signs and symptoms and pre- and post-treatment 
paresthesias SUlll-score sum-score VPT 
mean ±SD 0-1 2-6 6-12 mean ±SD 
pre-treatment 3% 1.0 ±1.4 76%24%0% 0.8 ±0.5 
post-treatment 
2 weeks 12% 1.7 ±1.5 53%47%0% 1.1 ±0.7 
3 months 55% 3.4 ±2.4 23% 68% 9% 2.4 ±2.0 
6 months 47% 2.7 ±2.0 29%64% 7% 1.9 ±1.5 
9 months 39% 2.4 ±2.3 44%48% 7% 1.7 ±1.0 
12 months 18% 1.2 ±1.2 64%36%0% 1.3 ±0.4 
Discussion 
The interpretation of data on the incidence and severity of cisplatin 
neuropathy is complicated because of differences in criteria for neuropathy, 
cumulative dose of cisplatin and prior or concurrent chemotherapy. With 
conventional doses of cisplatin 50-75 mg/m' per cycle and cumulative doses 
exceeding 300 mg/m', the reported incidence varies between 24% and 92% 
,.6.10.11,18,19. In one large study in which patients received a median cumulative 
dose of cisplatin between 500 and 600 mg/m', the overall incidence of any 
grade of neuropathy was 47%. Severe neurotoxicity characterized by a 
disability to walk occurred in 4% of the patients 3. Although neurotoxicity 
has emerged as one of the major complications in most studies on high-dose 
cisplatin 7.9.10.12.17.".", in some studies surprisingly either no or a low incidence 
of neuropathy is mentioned 8.23.". 
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The patients in our study participated in a trial on the feasibility of an 
intensive dosing schedule with a weekly administration of cisplatin, as 
reported previously". A mild or asymptomatic neuropathy was observed in 
16 out of 66 patients (24%) before the initiation of the treatment, which is 
similar to other reports on the incidence of neuropathy in cancer-patients ".". 
Following cisplatin exposure we found a mild to moderate neuropathy in 
71 % and severe neurotoxicity in 9% of the patients. 
We found a progression of the neuropathy after cessation of the therapy 
for a period of approximately 3 months, with subsequent but incomplete 
recovery thereafter. This phenomenon, also designated as "coasting", had 
previously been described and may reflect a time-lag in clinical manifesta-
tions of neuronal injury possibly related to pathological changes in axonal 
transport '7.20.10.3'. The long-term follow-up may explain the high incidence of 
neuropathy we observed. 
The main prognostic factor in our study for the severity of the neuropathy 
h I . d f· I . d b f 2.3.14.32 I was t e cumu atlve ose 0 CISP atm as reporte e ore . n contrast to 
others we did not find any relation between the severity of the neuropathy 
d I 33.)) h h an age, gene er or tumor type . T e pre-treatment VPT or t e co-treat-
ment with etoposide had no effect on the development of neuropathy either. 
We conclude that the severity of cisplatin neuropathy depends primarily 
on the cumulative dose. The observed progression of the neuropathy after 
cessation of the therapy implies the need for a prolonged follow-up up to at 
least 3 months after cisplatin exposure in future trials on cisplatin 
neuropathy. 
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Abstract 
It is uncertain whether intensive dosing schedules of cisplatin intended to 
attain a higher anti-tumor efficacy would lead to a change in severity of 
cisplatin-induced neuropathy. We assessed the development of neuropathy in 
three groups of patients treated with cisplatin in different dosing schedules. 
The severity of the neuropathy was determined by measurement of the 
Vibration Perception Threshold (VPT) before the treatment and during the 
follow-up until 2 to 12 months after the last cycle. 
Sixty-six patients were treated with an intensive weekly regimen of doses 
varying from 70-85 mg/m2 in one day (trial A), 21 patients with a three-
weekly combination chemotherapy containing cisplatin 75 mg/m2 in one day 
(trial B) and 20 patients with a three-weekly regimen containing cisplatin 20 
mg/m' for five consecutive days (trial C). The mean dose-intensity achieved 
was 59 mg/m'/week in trial A, 21 mg/m'/week in trial Band 33 mg/m'/week 
in trial C. 
The maximum post-treatment VPT correlated significantly with the pre-
treatment VPT (p < 0.001) and with the cumulative dose of cisplatin (p < 
0.001). Following the correction for these two variables the maximum post-
treatment VPT did not show a statistically significant association with dose-
intensity. 
These results suggest that neuropathy is not related to dose-intensity of 
cisplatin. This implies that a treatment with more intensive dosing schedules 
employing equal cumulative doses of cisplatin does not result in a 
concomitant increase of neurotoxicity within a cumulative dose range of 280-
675mg/m'. 
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Introduction 
Cisplatin is a cytotoxic agent effective against a wide spectrum of solid 
tumors. In vitro studies on human cancer-cell lines and a number of clinical 
trials have suggested a dose-response relationship for cisplatin 1.3. The 
administration of more intensive dosing schedules of cisplatin have become 
feasible, because potentially severe side-effects like vomiting and nephrotoxi-
city can now be reduced by potent anti-emetics, vigorous hydration and the 
use of hypertonic saline as a vehicle for cisplatin. 
Peripheral neuropathy is an important and dose-dependent side effect of 
cisplatin. This sensOlY neuropathy is characterized by paresthesias, numb-
ness, loss of tendon reflexes and a decrease in mainly thick-fiber mediated 
sensory qualities as vibration perception, fine-touch perception and 
proprioception. In some patients a disabling sensory ataxia may develop 4-7. 
The neuropathy continues to deteriorate up to approximately three months 
after the cessation of the therapy ("coasting"), with subsequent but 
incomplete recovery thereafter 8.10. It is presently uncertain if the severity of 
the neuropathy is influenced by alterations in cisplatin dosing schedules. In 
studies on the effect of dosing schedules and dose-intensity of cisplatin 
conflicting results on the development of neurotoxicity have been 
d11 ,12 reporte . 
We studied the development of neuropathy in three prospectively studied 
groups of patients treated with different dosing schedules of cisplatin. The 
Vibration Perception Threshold (VPT) was used as a quantitative measure of 
neuropathy. The VPT has been shown to be a reliable technique to monitor 
cisplatin neuropathy and other toxic neuropathies 9.13 0 1'. 
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Patients and Methods 
Three different studies on the effect of cisplatin were performed in our 
Institution during the same period of time. For inclusion, WHO performance 
status had to be 0-2 and life expectancy more than three months. Patients 
participating in these trials who had received at least four cycles of cisplatin 
were considered eligible for assessment of neurotoxicity. Excluded were 
patients with diabetes mellitus, alcohol abuse, earlier treatment with cisplatin 
and brain or leptomeningeal metastases. 
Patients in trial A participitated in a phase II study on the effect of weekly 
cisplatin on locally advanced or metastatic solid tumors (Chapter 2). 
Cisplatin was dissolved in 3% NaCl and administered in a 3-hour infusion 
with standard pre- and post-hydration. The administration took place in a 
weekly regimen in doses vmying from 70-85 mg/m'in six intended cycles. In 
some patients one week off-therapy was allowed after the third cycle. In most 
patients cisplatin was combined with etoposide in a daily dose of 50 mg 
orally two or three weeks per month which was continued after the cessation 
of cisplatin with a dose of 50 mg/m' daily at days 1-21 every four weeks for a 
maximum of four cycles. Trial B consisted of patients with ovarian cancer 
who were treated with cisplatin in a three-weekly schedule of 75 mg/m' in 
one day in combination with cyclofosfamide 750 mg/m' for six intended 
cycles. Trial C consisted of patients with testicular cancer or adenocarcinoma 
of unknown primmy, who were treated in a schedule of 20 mg/m' on five 
consecutive days every three weeks for four intended cycles. They were co-
treated with etoposide 120 mg/m' for three days every three weeks and 
bleomycin 30 mg weekly or ifosfamide 1.2 g/m' for five days three-weekly. 
Patients in trials Band C participated in two double-blind placebo-controlled 
studies on the effect of Org 2766, an ACTH( 4-9) analogue, on preventing 
cisplatin neuropathy. Only patients who received the placebo during 
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chemotherapy were used for comparison in this study. Nine patients from 
trial B received Org 2766 during the follow-up period starting one month 
after the last cycle of cisplatin. In trials Band C cisplatin was dissolved in 
NaCI 0.9% and administered in a 4-hour infusion with standard pre- and 
post-hydration. None of the patients in trial A,B and C received 
chemotherapy or other neurotoxic drugs during the follow-up period. 
The dose-intensity of cisplatin was calculated as the total amount of 
cisplatin administered divided by the total number of treatment weeks and 
was expressed in mglm'/week. Measurements of the VPT were performed 
before the stan of the treatment, at 2 weeks after the last dose of cisplatin and 
every 3 months up to 12 months thereafter. All patients had to have 
measurements of the VPT before the start of the treatment and during the 
follow-up until at least 2 months after the cessation of cisplatin treatment in 
order to be eligible for assessment of neurotoxicity. The VPT was measured at 
the dorsum of the second metacarpal bone of the left hand with a Vibrameter 
type III (Somedic AB, Stockholm, Sweden) and recorded in micrometers 
(Mm) of skin displacement. The Vibrameter uses a vibratory frequency of 100 
Hz and corrects for pressure-induced alterations of vibratOty amplitude. The 
method of limits was used to obtain the mean VPT and this was repeated 
three times ". 
Because of the skewed distribution of VPT, the natural logarithm was 
used for statistical analysis. The mean and standard deviation of VPT are 
reported in original units, but were derived from the mean and standard 
deviation of 10g(VPT). In this way they are less sensitive to outliers. The 
maximum VPT post-treatment per patient was calculated. Analysis of 
variance (ANOVA) was applied to study the relationship of the pre-treatment 
VPT with age, and regression analysis was used for the comparison of several 
prognostic factors with the maximum post-treatment VPT. Analysis of co-
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variance was used to study the association of dose-intensity and the 
maximum post-treatment VPT taking into account both total cumulative 
dose and the pre-treatment VPT. 
Results 
Sixty-six patients were treated in a weekly schedule (trial A), 21 patients 
in a three-weekly schedule (trial B) and 20 patients in a three-weekly 
schedule with administration divided over five consecutive days (trial C). 
Patient characteristics and the tumor type of the patients in these three 
groups are shown in table 3.l. The average age in group C is lower because of 
the tumor type (mainly younger males with testicular cancer). 
Table 3.1 
Patient characteristics and tumor types in trials A, Band C 
group A group B group C 
number of patients 66 21 20 
sex malelfemale SIllS 0/21 2010 
age mean years 55 58 29 
(range) (34-71) (28-73) (18-41) 
tumor type 
head and neck 15 
pleural mesothelioma 13 
colorectal 12 
nlelanolna 9 
non-small cell lung 8 
ovarian 21 
testicular 16 
adenocarcinoma of 
unknown primary 4 
other 9 
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Table 3.2 shows the dosing schedule, cumulative dose and dose-intensity 
of cisplatin and the pre- and post-treatment VPT in groups A, Band C. There 
is a difference in values for the mean pre-treatment VPT between these three 
groups. This difference is primarily due to the difference in age distributions 
of the patients in the three trials. Age shows a strong correlation with the pre-
treatment VPT (Spearman rank-correlation 0.65) as has been shown by 
others (16). The calculated dose-intensity of cisplatin achieved with each 
schedule is often lower than the scheduled dose-intensity because of dosage 
delay in some patients either by pre-scheduled interruption of chemotherapy 
or for reasons of toxicity. 
Table 3.2 
Dosing schedule, cumulative dose and dose-intensity of cisplatin and pre-
and post-treatment VPT in trials A,B and C 
group A group B group C 
closing schedule (mg/m') 70-85 75 5x20 
time-period weekly 3-weekly 3-weekly 
cumulative close mean (mg/m') 430 486 435 
(range) (280-510) (375-675) (400-900) 
dose-intensity (mg/m';'veek) 59 21 33 
(range) (26-82) (15-25) (26-34) 
pre-treatment VPT mean ±SD 0.8 ±0.5 0.6 ±0.3 0.3 ±0.1 
max.post-treat.VPT mean ±SD 2.4 ±l.9 3.6 ±3.7 l.3 ±l. 7 
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The variation in the cnmulative dose within each trial is due to the 
variation in the number of courses between patients within the trials. One 
patient in trial C was treated with a very high cumulative dose of 900 mg/m'. 
All other patients received doses between 280 and 675 mg/m'. Some patients 
in trial B had been treated with Org 2766 after the cessation of chemotherapy. 
The maximum post-treatment VPT of these patients was apparently not 
different from the other patients. The variation in the cumulative dose and 
dose-intensity, both between and within the trials was exploited to analyse 
the association of the maximum post-treatment VPT \\~th the cumulative 
dose, dose-intensity, age and pre-treatment VPT. Age (p< 0.001) or similarly 
the pre-treatment VPT (p< 0.001), and cumulative dose (p< 0.001) turned 
out to be strongly associated with the post-treatment VPT, explaining 40% of 
the variation. Given these factors, dose-intensity or treatment schedule 
showed no statistically significant association with the maximum post-
treatment VPT and, moreover, inclusion of these factors did not alter the 
regression coefficient for the cumulative dose. 
Figure 3.1 shows the relation of the maximum post-treatment VPT, 
adjusted for the pre-treatment VPT, and the cumulative dose of cisplatin with 
the regression line for the three schedules pooled. Exclusion of the outlier 
with the high cumulative dose in group C did not affect this line. Regression 
lines for each of the trials separately (not shown for clarity) were close to and 
not statistically significantly different from the line shown. 
This implies that in this study-population the level of neurotoxicity, as 
measured by the maximum post-treament VPT, depends primarily on the 
pre-treatment VPT or correspondingly the age of the patient, and the 
cumulative dose of cisplatin and not so much on the schedule employed or 
dose-intensity achieved. 
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Discussion 
The observation that the co-administration of hypertonic saline and a 
vigorous 
hydration can minimize cisplatin-induced nephrotoxicity has led to the 
use of higher doses and more intensive dosing schedules of cisplatin aiming 
at better tumor-control 2.3.17.18. However, one of the major complications in 
most studies on high-dose cisplatin is neurotoxicity 3.1I.l7.lO.", and the main 
factor for the severity of the neuropathy is the cumulative dose 5,6,13.", 
In the present study, we assessed prospectively neurotoxicity in patients 
treated with cisplatin in different dosing schedules with a follow-up until at 
least two but in the majority of cases until three to six months after the last 
cycle. We were able to confirm that the cumulative dose of cisplatin is the 
main prognostic factor for the severity of the neuropathy. 
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Several authors have attempted to reduce toxicity by modifying the dosing 
schedule of cisplatin. Short infusion schedules resulted in severe ototoxicity 
while schedules dividing the same total dose over five days did not, 
suggesting that ototoxicity is related to high peak levels of cisplatin ". A low 
incidence of gastrointestinal toxicity and nephrotoxicity with high-dose 
cisplatin in a five day continuous infusion has been observed ". Other studies 
reported that a schedule with an administration of 100 mg/m2 cisplatin on 
day 1 and 8 was less toxic than when the same total dose was given over five 
days (5x40 mg/m'). Less accumulation of cisplatin by employing larger time 
intervals seems one possible explanation "". 
A limited number of studies on the effect of dosing schedules of cisplatin 
on the development of neurotoxicity have been reported. Mollman et al. 
found an increased incidence of neuropathy in patients treated with high-
dose cisplatin (200 mg/m2 given over 5 days every 3 weeks) even with lower 
cumulative doses, as compared to patients treated with conventional dosing 
schedules (50mg/m2 every 4 weeks) suggesting that higher dose-intensities of 
cisplatin give rise to increased neurotoxicity n. In contrast, Cavaletti et al. 
found a lower incidence of neuropathy in patients treated with 50 mg/m2 
cisplatin given evelY week in 9 cycles than in patients treated with 75 mg/m2 
cisplatin every 3 weeks in 6 cycles 12. 
To determine the influence of dose-intensity on the severity of the 
neuropathy, we compared patients from three trials treated with dosing 
schedules differing in the dose-intensity of cisplatin administration. 
Compared to patients in groups A and B, the value for the mean pre-
treatment VPT was lower in patients of group C because of younger age. The 
difference in the pre-treatment VPT between groups A and B may reflect a 
higher incidence of pre-existing neuropathy in patients in group A, who all 
had advanced disease. The cause of this cancer-associated neuropathy is 
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uncertain but probably related to a-specific factors as cachexia, malnutrition 
and tumor progression lB,,,. Following correction for the pre-treatment VPT 
and the cumulative dose of cisplatin no significant difference in post-
treatment neuropathy was observed between patients in these three groups, 
suggesting that dose-intensity is not a factor of major importance for the 
development of neuropathy. It is well-known that the VPT increases with age 
16 and we confirmed this in our study. The patients in group C indeed had a 
lower mean post-treatment VPT, but they also had much lower pre-treatment 
VPT values, because of younger age. We found a strong significant 
correlation between the pre-treatment VPT and post-treatment VPT values, 
indicating that the change in the VPT may be a better measure for 
neuropathy than its absolute value. 
One reason for the discrepancies between studies on the influence of the 
dosing schedule 11,12 may be the length of the observation after the cessation 
of cisplatin cycles. As the neuropathy commonly continues to deteriorate up 
to approximately three months after the last cycle ("coasting") longer follow-
up periods are required, as employed in this study. Our results imply that the 
use of more intensive dosing schedules are not associated with an increased 
risk on neurotoxicity in the cumulative dose range used in our patients. 
These observations, however, should still be interpreted carefully, as patients 
from trial A received hypertonic saline as a vehicle for cisplatin 
administration and patients from trials Band C normal saline. Hypertonic 
saline has been shown to attenuate nephrotoxicity, but it is unknown 
whether a preventive effect on neurotoxicity exists and this may warrant 
further study. We would consider it improbable that the use of Org 2766 
after the cessation of cisplatin treatment in 9 patients from trial B has 
influenced the results, since we did not find a difference in the post-treatment 
VPT between patients either with or without Org 2766. Another point for 
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consideration is that the dose-range in this study population is limited and 
that the numbers of patients treated in trial Band C are rather small. The fact 
that the regression lines of the maximum post-treatment VPT versus the 
cumulative dose for the three schedules were not statistically significantly 
different indicates that there are at least no large differences. Larger studies, 
however, would be required in order to be able to detect small differences. 
We conclude that the severity of cisplatin neuropathy is mainly 
determined by the cumulative dose and seems not to be influenced by an 
increased dose-intensity of cisplatin administration. These results suggest 
that the anti-tumor effects of cisplatin may possibly be increased by the use of 
more intensive dosing schedules without a simultaneous risk on enhanced 
neurotoxicity in the cumulative dose range used in our study. 
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Abstract 
Docetaxel, a new semi-synthetic taxoid used as an antineoplastic agent, 
induced a predominantly sensory neuropathy in 20 out of 41 patients. We 
assessed neurotoxicity in all patients participating in four phase II trials 
conducted in our institution. The neuropathy was evaluated by a clinical 
sum-score for symptoms and signs and by measurement of the Vibration 
Perception Threshold (VPT). The severity of the neuropathy was graded 
according to the National Cancer Institute's 'Common Toxicity Criteria'. 
Neuropathic symptoms were mild in most patients. However, at 
cumulative doses above 600 mg/m2, three out of 15 patients developed a 
moderate neuropathy and one out of 15 patients a severe one. There was a 
significant correlation between the cumulative dose of docetaxel and the 
post-treatment sum-score (p ~ 0.002). We found no correlation between the 
post-treatment VPT and the clinical sum-score or between the post-treatment 
VPT and the cumulative dose of docetaxel. 
We conclude that docetaxel produces a mild and predominantly 
sensory neuropathy in a high proportion of patients treated. This 
neurotoxicity appeared to be dose-dependent and may be severe and 
disabling at higher dose levels. Determination of the VPT is not a reliable 
method to monitor docetaxel-induced neuropathy. 
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Introduction 
Docetaxel (Taxotere@, Rhone-Poulenc Rorer) is a new semi-synthetic 
taxoid prepared from a precursor, extracted from the needles of the European 
yew, Taxus baccata. Docetaxel has the same mechanism of action as 
paclitaxel (Taxo!), and both represent a unique class of chemotherapeutic 
agents. They inhibit tubulin depolymerization and promote microtubule 
assembly, thereby stabilizing microtubules. In contrast to paclitaxel, which is 
derived from the bark of the pacific yew, Taxus brevifolia, docetaxel comes 
from a renewable source. In vitro, docetaxel is more potent than paclitaxel'. 
In preclinical studies, docetaxel has demonstrated anti-tumor activity 
against a wide variety of solid tumors '. phase I and II trials have shown 
significant clinical activity in ovarian carcinoma 1,3, breast cancer 4.8, 
melanoma 9, non-small-cell lung cancer 10.11 and small-cell lung cancer ". 
Neutropenia is the dose-limiting toxicity in most studies. Other side-effects 
are hypersensitivity reactions, cumulative fluid retention syndrome mainly 
characterized by peripheral edema, gastrointestinal toxicity, skin toxicity and 
onchylysis. 
Lipton et al. reported neuropathy as a dose-dependent side-effect of the 
treatment with paclitaxel ". Mild peripheral neurotoxicity induced by 
docetaxel was present in phase I and phase II studies but there have been no 
attempts to further characterize the neuropathy. Our institution participated 
in four multicentre phase II trials on the activity of docetaxel as first or 
second line chemotherapy in metastatic or locally advanced solid tumors. We 
assessed neurotoxicity prospectively in all our patients entered in these trials. 
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Patients and methods 
Patients were required to have metastatic or locally advanced cancer for 
which no appropriate therapy was available. Other inclusion criteria were age 
18-75 years, WHO performance status 0-2, normal organ functions and a life 
expectancy of more than three months. All patients granted informed consent 
according to institutional rules. Patients with symptomatic peripheral neuro-
pathy grade 2 or more according to the "National Cancer Institute (NCO 
criteria" and patients with brain or leptomeningeal metastases were excluded. 
Docetaxel was supplied by Rhone-Poulenc Rorer. In three trials it was 
administered as a one-hour infusion at a dose of 100 mg/m2 every three 
weeks. In one trial for patients with breast cancer the dose per cycle was 
divided and given on day one and day eight every three weeks. Only in the 
latter study patients were randomized to receive premedication with 
methylprednisolone. No other neurotoxic drugs were used during the study 
or follow-up period. 
The severity of the neuropathy was evaluated by a questionnaire for 
neurological symptoms, by standardized neurological examination and by 
measurements of the Vibration Perception Threshold (VPT) before the start 
of the treatment, after every two cycles, at two weeks after the last dose of 
docetaxel and every three months thereafter. The questionnaire established 
separately absence (0) or presence (1) of paresthesias, numbness, loss of 
dexterity and unsteadiness of gait. On sensOlY examination position sense, 
vibration sense, pin-prick sensation, Romberg's sign, Romberg's sign with 
heel-to-toe stand and tendon-reflexes of the legs were each scored as normal 
(0) or abnormal (1). A sum-score for these signs and symptoms was calcu-
lated (minimum 0, maximum 11). The severity of paresthesias was graded on 
a 5-point scale (O~no, I~temporary, 2~continuous & light, 3~severe, 
4~unbearable). Sensory loss was defined as an abnormal test on either 
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position sense or vibration sense or pin-prick sense. Patients were asked 
whether they experienced Lhennitte's sign or pain. The distal muscle 
strength in the lower extremities was tested. Motor signs were defined as the 
presence of objective weakness. The severity of the neuropathy was scored 
according to the NCI Common Toxicity Criteria (CTC) for sensory 
neuropathy (O=no symptoms or signs, l=mild paresthesias,loss of deep 
tendon reflexes, 2=moderate paresthesias,objective sensory loss, 3=severe 
paresthesias,sensory loss interfering with function). The VPT was measured 
at the dorsum of the second metacarpal bone of the left hand with a 
Vibrameter type IV (Somedic AB, Stockholm, Sweden) and recorded in 
micrometers (flm) of skin displacement. This Vibrameter uses a vibratory 
frequency of 100 Hz and corrects for pressure-induced alterations of 
vibratory amplitude. The method of limits was used to obtain the mean VPT 
and this was repeated three times ". The VPT has been shown to be a reliable 
technique to monitor cisplatin neuropathy and shows a good correlation with 
the sum-score of neuropathic signs and symptoms as observed previously 15-17. 
It has been employed to quantify paclitaxel-induced neuropathy 18. 
As only nine patients were evaluated on two or more occasions post-
treatment, the first post-treatment evaluation was used as a primary endpoint 
for the assessment of the neurotoxicity. Cycles of docetaxel given after the 
last neurological evaluation, which occurred in a few patients, were not 
counted in the analysis and excluded from the calculation of the cumulative 
dose. 
The mean sum-score and mean VPT for the whole group pre-treatment 
and post-treatment were calculated. Because of the skewed distribution of the 
VPT, the natural logarithm was used for statistical analysis. The mean and 
standard deviation of the VPT are reported in original units, but were derived 
from the mean and standard deviation of 10g(VPT). 
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Analysis of variance (AN OVA) was applied to study the relationship of 
the pre-treatment VPT with clinical parameters, for example with previous 
treatment with cisplatin. This technique was also applied to study the 
association between the cumulative dose of docetaxel and the post-treatment 
sensory sum-score or VPT or the difference with the pre-treatment scores. In 
addition Spearman rank-correlations were calculated to determine the 
strength of the association between ordinal variables as the cumulative dose, 
VPT and sum-score. 
Results 
Fifty-five patients from our institution were entered in the clinical trials 
on docetaxel. Fourteen of these 55 patients were excluded from the 
assessment of neurotoxicity because of lack of a pre-treatment evaluation 
(n~3), treatment with less than two cycles (n~ 7) or lack of evaluation after 
the second cycle (n~4). 
Patient characteristics, tumor-type and previous chemotherapy of 41 
patients evaluable for the present analysis are shown in table 4.l. Twelve 
patients had not been treated previously with chemotherapy. Nine patients 
had received prior anti-tumor treatment with cisplatin. The other patients 
had been treated with non-neurotoxic chemotherapy. One patient had 
dIabetes mellitus and one patient reported alcohol abuse. 
Twenty-five patients received 2-4 cycles of docetaxel, lO patients 6-8 
cycles and six patients 9-11 cycles before their last evaluation. All patients 
started treatment at a dose of 100 mg/m2 docetaxel per cycle, but some 
patients required dose-reduction because of adverse effects. In the 11 breast 
cancer patients this cycle dose was administered in the day 1-8 schedule. The 
cumulative dose of docetaxel was less than 300 mg/m2 (range 150-300 
mg/m2) in 14 patients, 300-600 mg/m2 in 12 patients and more than 600 
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mg/m' (range 600-1100 mg/m')in 15 patients. The median duration of the 
follow-up after the last cycle was 27 days (range 7-310 days). 
Table 4.1 
Patient characteristics and tumor type 
number of patients 
sex male/female 
age mean years 
(range) 
tumor type 
breast 
ovarian 
sarcoma 
head and neck 
bladder 
melanoma 
colorectal 
previous treatment 
cisplatin 
other chemotherapy 
41 
14/27 
53 
(28-73) 
11 
10 
7 
5 
5 
2 
1 
9 
20 
Before the start of the treatment four patients had a mild neuropathy 
which was due to previous chemotherapy with cisplatin. In the other five 
patients with previous cisplatin treatment as well as in the patients with 
diabetes mellitus or alcohol abuse no neuropathic symptoms and no or only 
minor signs could be detected. 
Table 4.2 shows the incidence of neuropathic signs and symptoms at the 
first post-treatment evaluation. At the first post-treatment evaluation 
paresthesias were encountered in 21 patients (51%): in the hands (n~5), in 
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the feet (n~2), in both hands and feet (n~14). Eight patients suffered from 
pain in either hands or feet, which was felt to be secondary to neuropathy. 
Numbness developed in 13 patients (34%) and loss of dexterity in 14 patients 
(35%). In nine patients (23%) the sensOlY neuropathy led to unsteadiness of 
gait. Lhermitte's sign developed in two patients not pre-treated with cisplatin 
during the treatment with docetaxel, in one patient accompanied by severe 
sensory neuropathy after seven cycles of docetaxel and in the other as the 
only symptom after one cycle. Objective sensory loss was detected in 11 pa-
tients (30%) and objective loss of motor strength in two patients (5%). Loss 
of ankle jerk was found in 18 patients (51%), loss of both ankle and knee 
jerks in 16 patients (41%). 
Table 4.2 
Neuropathic signs and symptoms at first 
post-treatment evaluation 
paresthesias 
grade 1 
grade 2 
grade 3 
grade 4 
pain 
numbness 
loss of dexterity 
unsteadiness of gait 
Lhennitte's sign 
sensory loss 
motor signs 
Romberg's sign 
loss of knee jerk 
loss of ankle jerk 
N (%) 
21/41 (51) 
8/40] 
13/38 
14/40 
9/40 
2/40 
11137 
2/38 
1/37 
16/40 
18/35 
10' 
ll' 
o 
o 
(20) 
(34) 
(35) 
(23) 
(5) 
(30) 
(5) 
(3) 
(41) 
(51) 
') Excluding 1 patient with pre-e .. xisting paresthesias grade 1 
1) including 1 patient with pre-existing paresthesias grade 1 
J) Patients with this sign or symptom at pre-treatment evaluation or missing data are e.xcluded 
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Table 4.3 shows the mean increase in the sensory sum-score, the mean 
relative increase in the VPT value, the severity of paresthesias and the CTC-
neurosensoly-grade at first post-treatment evaluation classified by cumulative 
dose. According to CTC criteria, 20 patients developed a sensory neuropathy. 
In the groups with a cumulative dose below 600 mglm' nine out of 26 
patients showed a mild sensory neuropathy. Out of 15 patients who had 
received a cumulative dose above 600 mglm', 11 patients developed a sensory 
neuropathy which was graded mild in nine patients and moderate in two 
patients. In this group with high cumulative doses, four out of seven patients 
with prior cisplatin treatment developed a neuropathy in contrast to seven 
out of eight patients without previous cisplatin treatment. In three patients 
treatment with docetaxel had to be discontinued because of neurotoxicity 
and in five patients because of other toxicities. 
Table 4.3 
Severity of neuropathy in relation to cumulative dose docetaxel 
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sensory sum-score 
. . Increase 
mean (±SD) 
VPT 
relative increase (%)1 
mean (±SD) 
paresthesiasJ 
grade 1 
grade 2 
grade 3 
grade 4 
eTC neurosensory3 
grade 1 
grade 2 
grade 3 
< 300 Illg/Ill' 300-600 Illg/m' 
N= 14 N=l2 
l.S±1.2 
35 ±89% 
S 
1 
2 
2.9 ±2.5 
7 ±38% 
3(2)' 
3(5) 
7 
>600mg/m' 
N=lS 
3.9 ±2.7 
34 ±87% 
2(1) 
7(6) 
-(2) 
-(1) 
9(7) 
2(3) 
-(1) 
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') difference between first post-treatment and pre-treatment score. 
1) relative difference between first post-treatment and pre-treatment score. 
J) incidence at first post-treatment evaluation; in case of pre-existing graded toxicities only 
IIigher grades are counted. 
4) () = lIwllbers when nJCLximwu scores post-treatment are considered. 
Nine patients had two or more post-treatment evaluations. In four of 
these patients neuropathy worsened during the follow-up, of which two 
patients developed a moderate neuropathy and one patient a severe one. 
A clear correlation between the pre-treament value of the VPT and the 
pre-treatment sum-score was found (Spearman rank-correlation R, = 0.64, 
P < 0.001). This association was primarily due to higher scores on both the 
VPT and sum-score in patients with previous cisplatin treatment. Following 
docetaxel treatment no correlation was found between the relative increase in 
the VPT and the increase in the sum-score (R, = 0.08, P > 0.20). The 
cumulative close of clocetaxel showecl a statistically significant correlation 
with the increase in the sum-score (R, = 0.39, P = 0.01), but the change in the 
VPT showed no correlation with the cumulative dose (R, = 0.08, P > 0.20). 
Some increase in the VPT was seen after cumulative doses of more than 600 
mglm' , but this is far from statistically significant. Moreover, there is no 
trend apparent in the increase of the VPT with increasing dose (Table 4.3). In 
contrast, the sensory sum-score showed an increase even at lower cumulative 
doses of docetaxel (Figure 4.1). The increase in sensory sum-score was 
higher in the patients treated with the day 1-8 schedule in comparison to the 
other patients, but this difference was not statistically significant. 
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Figure 4.1 
Tile mean change (± SE) in SCIlS01Y sum-score after treatment with docetaxd (Taxotere) in 
relation to the cumulative dose docelaxel (mg/m2). The numbers above tile h01izolital axis 
indicate the lIumber of patients evaluated. 
Discussion 
All patients were treated with docetaxel at a cycle dose of 100 mg/m', but 
differed in the total cumulative dose they received. Forty-nine percent of the 
patients showed a sensory neuropathy at the first post-treatment evaluation. 
In four patients the neuropathy worsened during the follow-up. As we saw 
only nine patients more than once post-treatment, the neurotoxicity may 
have been underrated. The neuropathy was mild in most patients, but at 
cumulative dose levels above 600 mg/m', three out of 15 patients developed a 
moderate neuropathy, and one out of 15 a severe sensory neuropathy 
interfering with function. Two of these patients also showed severe motor 
involvement. The neuropathy was the dose-limiting toxicity in three patients. 
The most extensively studied taxoid, paclitaxel, causes a predominantly 
sensory, both axonal and demyelinating, neuropathy which is related to both 
the single dose and cumulative dose of paelitaxel 13.18. Its pathophysiologic 
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mechanism is presumably related to the promotion of microtubule 
aggregation in neurons, axons and Schwann cells, possibly initiated at the 
level of the dorsal root ganglia 13, 
In phase I clinical trials on docetaxel, mild neurotoxicity was present 
sporadically but most patients received low doses and a limited number of 
courses 19,", New et al. reported on a phase IIII trial of 186 patients treated 
with a wide range of cumulative doses (50 mg/m' - 720 mg/m') and dose 
levels (10 mg/m' - 115 mg/m') ", Twenty-one of their patients (11%) 
developed a mild to moderate sensOIY neuropathy affecting mainly large fibre 
function, In 10 patients there was motor involvement. In four phase II trials 
in patients with non-small-cell lung carcinoma, small-cell lung carcinoma 
and melanoma treated with docetaxel at a dose of 100 mg/m' every three 
weeks, a usually mild sensory neuropathy developed after three or four cycles 
in 37%-44% 9.12, In one of these trials, a severe neuropathy developed in four 
out of 29 patients, possibly related to alcohol abuse in three of them ", 
Docetaxel induced neuropathy resembles the sensory neuropathy 
secondary to paclitaxel 13,18, In our series, signs and symptoms included 
paresthesias, numbness, loss of sensory qualities and tendon reflexes in both 
upper and lower extremities, Some patients had pain in hands and feet and 
two patients developed Lhermitte's sign, which is common with cisplatin 
neuropathy 23,,,, but not observed previously with either paclitaxel or 
docetaxel. The neuropathic signs and symptoms correlated strongly with the 
cumulative dose of docetaxel. Within the cumulative dose-range used in our 
study, the neuropathy was mild in most patients, We found no apparent 
relation with prior treatment with cisplatin, 
We did not establish a significant relation between the VPT and the 
severity of docetaxel-induced neuropathy, Although the VPT -values were 
higher with high cumulative doses, the poor association with clinical signs 
and symptoms indicated that the VPT is not a good indicator of docetaxel-
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neuropathy. Several reports demonstrated that the VPT is a reliable indicator 
of cisplatin-neuropathy IH7. This method has also been used with paclitaxel 
induced neuropathy 18. In docetaxel-neuropathy small fibre function might be 
most compromised, suggested by the relative high number of patients with 
associated pain, unusual in cisplatin neuropathy which affects mainly thick 
myelinated fibres. 
We conclude that docetaxel induces a frequent dose-dependent 
predominantly sensory neuropathy. The neuropathy is mild in most patients. 
At higher cumulative dose levels, patients may develop a severe and disabling 
neuropathy. 
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Abstract 
Docetaxel, a semi-synthetic taxane with promising clinical antitumor 
activity, may cause a usually mild sensory neuropathy. We report six patients 
who developed a more severe neuropathy following the treatment with 
docetaxel. The neurological signs and symptoms and the clinical course of 
this new type of chemotherapy-induced neuropathy are discussed in detail. 
The clinical picture is nearly always dominated by a sensory neuropathy, 
but in more severe cases motor weakness may occur. In some patients 
Lhermitte's sign develops. Signs and symptoms are usually reversible after 
discon tinuation of docetaxel administration. However, after the cessation of 
the treatment symptoms may first worsen before improvement occurs. This 
neuropathy is likely to be related to the effect of docetaxel on microtubule 
functions in dorsal root ganglion cells, axons and Schwann cells. 
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Introduction 
Docetaxel (Taxotere®; Rhone-Poulenc Rorer) is a new semi-synthetic 
analogue of paclitaxel (Taxo!"). These taxanes represent a unique class of 
chemotherapeutic agents which exert their action by inhibiting tubulin 
depolymerization and promoting microtubule assembly, thereby stabilizing 
micro tubules. In Phase I and II clinical trials docetaxel has demonstrated 
interesting clinical activity in ovarian cancer 1,\ breast cancer H, melanoma 81 
non-small-cell lung cancer 9.10 and small-cell lung cancer II. In most studies 
neutropenia is the dose-limiting toxicity. Other side-effects include 
hypersensitivity reactions, a fluid retention syndrome, gastrointestinal 
toxicity and skin toxicity. 
A usually mild and predominantly sensory axonal neuropathy is reported 
in phase I and phase II studies. However, occasionally a more severe 
neuropathy develops, causing painful paraesthesias and weakness. To our 
knowledge, no attempts have been made to describe docetaxel induced 
neuropathy in detail. We describe six patients with a moderate or severe 
docetaxel-induced neuropathy. All patients received docetaxel at a dose of 
100 mg/m' given as an I-hour infusion which was repeated every three 
weeks, without corticosteroid pre-medication. They were all treated within 
clinical trials and, as a part of this, were undergoing neurological 
examinations at baseline and on regular intervals during and after the 
treatment. Based on these observations we will discuss the characteristics of 
docetaxel neuropathy. Patient's characteristics, signs and sYlllptoms, 
e1ectrophysiological findings and the course of the neuropathy are 
summarized in table 5.1. 
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Case reports 
Patient A is a 71-year-old man who developed para-aortallymphnode 
metastases from urothelial bladder cancer. The baseline neurological 
examination performed before the start of chemotherapy was normal, except 
for the absence of ankle jerks. There was no histOlY of alcohol abuse or 
diabetes mellitus. He received nine cycles of docetaxel. After three cycles he 
reported numbness and a heavy feeling in his feet. His nails were painful due 
to onycholysis. At examination he showed loss of vibratory perception at his 
feet and loss of knee jerks. After six cycles he noted light paraesthesias and 
numbness in his hands, and clumsiness. He showed some unsteadiness of 
gait and loss of joint position sense in his toes. His muscle strength was 
normal. Despite complete remission of the tumor, the chemotherapy with 
docetaxel was discontinued after nine cycles because of progressive sensory 
disturbances of his feet and unsteadiness of gait. At examination a mild drop 
of both feet was noted. He also had fluid retention causing severe edema in 
his legs. 
In the first months after the last cycle he gradually developed painful 
paraesthesias in his hands and legs. He was unable to walk. On examination 
he showed a paraparesis of both legs, a proximal muscle strength MRC grade 
3 and distal grade 4, a mild paresis of hand muscles and total areflexia. 
Hypaesthesia was found below the knees and to mid-palm. Vibratory 
perception was absent in his hands and legs. Nerve conduction studies and 
an EMG revealed a severe and mainly axonal neuropathy with abundant 
denervation potentials, with a slight decrease of the nerve conduction 
velocities. An abdominal CT-scan showed complete regression of para-aortal 
metastatic lymphnodes, an MRI-scan of the thoracic and lumbar spine was 
normal. No other cause for the neuropathy than the chemotherapy with 
docetaxel was found. 
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Table 5.1 
Signs and symptoms, EMG and course of docetaxel induced neuropathy in six patients 
age- cumulative I" symptom other signs and symptoms EMG course 
/sex dose 
A 900 mg/m 
, 
numbness pain, pauesthesias, se\'ere fibrillations ++ progression after 
71&1 feet weakness, total arefIn.ia, N Med: dI4.0ms, stop treatment 
(300 mg/m') loss vibratory + joint MNCV 39m/s, N Per: complete recovery 
position sense, MUAP absent (distal 
hypaesthesia sHill.) N Tib: dI4.6ms, 
MNCV37m/s 
B 700 mg/m 
, 
paraesthesias numbness, loss dexterit}', not done incomplete 
601F hands loss ankle + knee jerks, recovery 
(700 mg/m') loss vibratory + joint 
pOSition sense, Romberg's 
sign 
C 700 mg/m 
, 
paraesthesias numbness, lhennitte, fibrillations + N Med, unknown 
69/M hands + feet paresis, areflexia, N Sur: SNAP absent 
(400 mg/m') hypaesthesia, loss N Per: dl 5.0I1ls, 
vibratory sense MNCV32m1s 
H-renex M soleus: 
absent 
D 600 mg/m 
, 
paraesthesias pain, numbness, loss not done progression after 
471i\1 hands + feet ankle jerks, loss dexterity, stop treatment 
(200 mg/m') uncertainty walking, loss 
Vibratory + joint position 
sense 
E 100 mg/m 
, 
numbness hypaesthesia, areflexia, SNCV: N Med 45m1s, symptoms after 1 
31/F hands + feet Romberg's sign N Uln 40m/s, N Sur cycle some 
(l00 mg/m1) 33m1s improvement after 
stop treatment 
F 500 mg/m' Lhefmitle paraesthesias, loss ankle + not done improvement after 
40/F (100 mg/m') knee jerks stop treatment 
dl = distallatellcy, MNC\' = motor nerve conduction velocity, SNAP = sensa!), lIerve actio 
potential, MUAP = 11I0tor ullit action potential, 
N Med = Median nerve, N Uln = Ulnar nerve, N Sur = Sural nerve, N Per::;: Peroneal nerve, 
N Tib = nbialllCI1'C 
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The signs and symptoms gradually improved spontaneously. Five months 
after the last cycle the pain had disappeared and he was able to walk 
unassistedly. The EMG at that time showed no denervation potentials 
anymore, but a persistent mild slowing of the nerve conduction velocities. He 
recovered almost completely, being able to walk and bicycle for several hours 
10 months after the last cycle. 
Patient B, a 60-year-old woman, developed liver-metastases from ovarian 
cancer. She had been treated with chemotherapy containing cisplatin one 
year before. The baseline neurological examination before the docetaxel 
treatment showed no signs or symptoms of a neuropathy. She received seven 
cycles of docetaxel. After four cycles she reported painful and discolouring 
nails, without signs or symptoms of neuropathy. The chemotherapy was 
discontinued after the seventh cycle because of progressive cancer. At that 
time the patient reported mild paraesthesias in her hands, and at examination 
a loss of ankle jerks was found. The paraesthesias subsequently progressed, 
and the patient complained of numbness in hands and feet with loss of 
dexterity. At examination four months after the last cycle she showed loss of 
vibratory perception and joint position sense at her feet, a positive Romberg's 
sign and loss of knee jerks. The muscle strength was normal. At further 
follow-up these signs and symptoms improved. Nine months after the last 
cycle the patient reported normal dexterity, but still complained about 
paraesthesias. She died one year after the last cycle from progressive disease. 
Patient C, a 69-year-old man, had initially been treated for bladder cancer 
with local radiotherapy. He subsequently developed multiple bone metastases 
and local progression with infiltration into the left lumbosacral plexus. At the 
neurological examination there was a mild paresis MRC grade 4 of the left 
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foot dorso-flexors, absence of the left ankle jerk and hypaesthesia at the 
lateral foot. He then received seven cycles of docetaxel. After four cycles he 
reported mild paraesthesias in his hands, and at examination loss of vibratory 
perception at his toes and loss of tendon reflexes at his legs were found. 
Despite a partial tumor response, the chemotherapy was discontinued after 
the seventh cycle because of progressive neuropathic symptoms, consisting of 
numbness and severe paraesthesias in hands and feet, tingling in hands and 
feet with flexion of the neck and difficulty in walking. At examination three 
weeks after the last cycle a paralysis of left foot dorso-flexors and MRC grade 
3 weakness of foot flexors, complete areflexia and hypaesthesia of hands and 
legs below the knees were found. The EMG and nerve conduction studies 
revealed a severe mainly sensory neuropathy and a lesion of the left ischiadic 
nerve. Progression of the tumor was diagnosed three months later, thereafter 
the patient was lost to the follow-up. 
Patient D, a 47-year-old man \vith Recklinghausen's disease type 1, 
initially underwent a resection of a malignant pleural schwannoma. One year 
later he received two cycles of ifosfamide and adriamycine because of a local 
relapse with cutaneous metastases, without response. Therefore, the 
treatment was changed and he received six cycles of docetaxel. 
Before the start of the therapy \vith docetaxel he had no signs or 
symptoms of neuropathy. After two cycles he experienced temporary 
paraesthesias in hands and feet. After four cycles, ankle jerks were lost and 
there was a mild impairment of the joint position sense of the toes. Mild 
paraesthesias in hands and feet recurred after the sixth cycle. The docetaxel 
was stopped because of progressive disease, but the neuropathic symptoms 
continued to progress gradually. He complained of painful paraesthesias, 
numbness, loss of dexterity and uncertainty in walking. The exantination two 
88 
Chapter 5: Docetaxel Neurotoxicity: Clinical Characteristics 
months after the last cycle revealed impairment of the vibratory perception 
and joint position sense at the feet, normal strength and loss of knee and 
ankle reflexes. Four months after the last cycle he died. 
Patient E, a 31-year-old woman, developed liver-metastases from breast 
cancer. Because of progressive disease during chemotherapy with 
cyclofosfamide and adriamycine the treatment was changed to docetaxel after 
six cycles. Three days after the first cycle she noted numbness in her hands 
and legs. Examination revealed hypaesthesia below the knees and in her 
hands, generalised areflexia, positive Romberg's sign and normal muscle 
strength. Blood examination showed mild elevated liver enzymes and mild 
anaemia, but no other abnormalities. Examination of CSF was unremarkable. 
Nerve conduction studies showed only a slowing of the sensory nerve 
conduction velocities. Because of toxicity the treatment was discontinued. 
She reported some improvement in the neuropathic symptoms after this 
period. She died shortly afterwards. 
Patient F was a 40-year-old woman with metastatic breast cancer. After 
first- and second line chemotherapy and hormonal therapy, the treatment 
with docetaxel was started because of progressive disease. She received five 
cycles. At base-line examination there were no neuropathic signs or 
symptoms. Shortly after the first cycle she noted painful tingling in hands 
and feet triggered by neck flexion. A cervical MRI showed two small 
metastases in the sixth and seventh vertebral body, without epidural 
compression. The serum vitamin B12 value was normal. Besides this 
Lhermitte's sign she had no other neurological symptoms, but she developed 
mild paraesthesias in her fingers and feet during the next three cycles. At 
examination a loss of knee and ankle jerks was found. Because of toxicity 
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(onycholysis, anorexia, fatigue, polyneuropathy) the treatment was 
discontinued after five cycles. Lhermitte's sign persisted up to two months 
after the cessation of the chemotherapy, but thereafter gradually disappeared. 
Discussion 
We present six cases of neuropathy induced by chemotherapy with 
docetaxel, a new semi-synthetic taxane. The currently most extensively 
studied taxane, paclitaxel, causes a predominantly sensory, both axonal and 
demyelinating neuropathy which is related to both single dose and 
cumulative dose of the drug I,.ll. Its pathophysiologic mechanism is 
presumably related to the promotion of microtubule aggregation in neurons, 
axons and Schwann cells 12. In phase I and II clinical trials on docetaxel, a 
mild dose-dependent neurotoxicity affecting mainly sensory functions has 
been observed 8.11.14-18. In a phase II study on docetaxel conducted in our 
institution 20 out of 41 evaluable patients treated with cumulative doses 
ranging 150-1100 mg/m' developed a usually mild neuropathy 17. However, 
following the treatment with a cumulative dose above 600 mg/m', we 
observed in four out of 15 patients a moderate or severe neuropathy inter-
fering with function 17. These four patients are presented in this paper (A,B,C 
and D) together with a patient who had Lhennitte's sign (F) and a patient 
who participated in another trial on docetaxel (E). 
The clinical picture in our patients was dominated by sensOlY signs and 
symptoms. Symptoms usually started with paraesthesias and numbness in 
hands and feet, sometimes interfering with dexterity and steadiness of gait. At 
this stage the symptoms were usually easily differentiated from symptoms 
caused by edema and skin or nail disorders. Loss of tendon reflexes and 
vibratory perception were an early sign. Loss of joint position sense and 
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sensory ataxia developed with further progression of the neuropathy. Often 
the paraesthesias were painful, suggesting involvement of small fibre. 
In patient A the severe sensory neuropathy was accompanied by loss of 
strength leading to asevere disability. New et al. found evidence of motor 
weakness in half of the patients with docetaxel neuropathy 18. In patient C the 
muscle weakness was associated with a lesion of the ischiadic nerve 
superimposed on a sensory neuropathy. Although he had involvement of the 
sciatic nerve at an earlier stage of his disease, at the time he developed motor 
weakness there was no evidence of tumor recurrence. The sciatic nerve may 
have been more vulnerable to neuropathy. However, this must be stated with 
some restraint, as tumor progression was diagnosed five months later. 
Two patients developed Lhennitte's sign during the treatment with 
docetaxel. Lhennitte's sign is common with cisplatin neuropathy 19.>0 and may 
represent involvement of either the dorsal root ganglia or posterior columns 
I'. It has not been reported previQusly with either paclitaxel or docetaxel. 
Neither of these patients had been treated with cisplatin, and no other cause 
for Lhennitte's sign was found. 
The course of docetaxel-induced neuropathy was notable. Signs and 
symptoms appeared during chemotherapy after two to four cycles and 
progressed gradually with new cycles. In most patients the main factor 
appeared to be the cumulative dose of docetaxel. Patient E, however, showed 
a moderate neuropathy after only one cycle, suggesting an individual 
susceptibility. In most patients treated with docetaxel neuropathy symptoms 
improve 6-8 weeks after treatment discontinuation 18. In contrast, in three of 
our patients (A, B and D) the neuropathy progressed for several months after 
the cessation of the treatment. This phenomenon, or "coasting", is also 
present following the treatment with cisplatin and may be related to 
pathological changes in axonal transport 21-". In most patients with sufficient 
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follow-up neuropathic signs and symptoms were at least partly reversible. 
Despite a severe weakness, recovery was almost complete in patient A. 
Although paclitaxel and docetaxel neuropathy is mainly a sensory axonal 
neuropathy, the electrophysiologic data in our patients and those of others 
suggest that in more severe cases of docetaxel neuropathy a mixed axonal-
demyelinating neuropathy may develop 18. The precise mechanism of this 
neuropathy is unknown, but based on the resemblance with paclitaxel in its 
mechanism of action it might be caused by the effects of docetaxel on 
microtubules. The predominance of sensory features with onset 
simultaneously in hands and feet in many of our patients suggests that this 
neuropathy may not be a dying back, length dependent neuropathy, but a 
neuronopathy primarily affecting the dorsal root ganglion ". 
In conclusion, neuropathy is not a predominant side-effect of docetaxel 
17.18. However, espeCially following the treatment with a high cumulative dose, 
some patients may develop a severe and disabling neuropathy. Further study 
for risk factors of docetaxel neuropathy is of high clinical relevance, in view 
of the continuously accumulating evidence that docetaxel holds promise as 
an effective antineoplastic agent 
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Abstract 
Specific causes for Lhermitte's sign (LS) in cancer patients are spinal cord 
compression, radiation therapy to the spinal cord and cisplatin 
chemotherapy. We observed a transient LS in 5 out of 87 patients treated 
with more than two cycles of lOOmglm' docetaxel (Taxotere). LS developed 
either concurrent or after the onset of docetaxel induced sensory neuropathy, 
and disappeared after the discontinuation or dose reduction of 
chemotherapy. 
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Introduction 
Although more properly designated a symptom than a sign, Lhermitte's 
sign (LS) is an electric shock-like sensation which shoots down the back and 
into the limbs 'when the neck is flexed. LS may be seen in a variety of 
disorders of the spinal cord, such as demyelinating disease, vitamine B12 
deficiency, spinal cord compression and spinal cord tumors. In cancer 
patients, it may also develop following radiotherapy of the spinal cord and 
after chemotherapy with cisplatin '. We describe five patients who developed 
LS during the treatment with docetaxel (Taxotere), a new cytotoxic agent. 
Patients and methods 
All patients participated in phase II trials on docetaxel chemotherapy. 
They received docetaxel in three-weekly cycles: patient A with 50 mg/m2 on 
day 1 and day 8 of each cycle, Patients B-E with 100 mg/m2 docetaxel on day 
1 as a one-hour infusion. As a part of these studies all patients were evaluated 
prospectively for neurotoxicity with baseline and follow-up neuroexams, 
including specific questioning for the presence of LS. In each of the presently 
described patients the neurological baseline investigations were normal. 
Results 
Patient A, a 40-year-old woman was treated for recurrent metastatic 
breast cancer with docetaxel. Shortly after the first cycle of docetaxel she had 
transient paresthesias in her feet; she also noticed that neck flexion triggered 
a painful tingling in her hands and feet. No other neurological symptoms 
were present. The MRI of the cervical spine showed two small bone 
metastases without spinal cord compression. Serum vitamin B12 was normal. 
Following further treatment she developed persistent paresthesias in her fin-
gers and feet. After four cycles, loss of tendon reflexes was found. Following 
the next cycle the treatment was discontinued because of toxicity. LS and 
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paresthesias persisted up to two months after the cessation of the chemo-
therapy, and disappeared thereafter. Shortly afterwards, progressive disease 
was diagnosed and she was lost to the follow-up. 
Patient B, a 47-year-old woman was treated with docetaxel for recurrent 
metastatic breast cancer. After two cycles she developed paresthesias in 
fingers and toes. Physical examination showed the absence of tendon reflexes 
and loss of vibration sense. Symptoms progressed during the next cycles. 
After five cycles she had numbness of fingers and toes, paresthesias in the 
entire feet, slight proximal weakness, and Romberg's sign was positive. Now, 
flexion of the neck provoked paresthesias in the entire legs. Nerve 
conduction velocity (NCV) studies showed a sensori-motor axonal 
polyneuropathy. Because of toxicity the treatment was discontinued. In the 
next months the paresthesias and LS disappeared although some numbness 
of the fingers persisted. 
Patient C, a 51-year-old woman with metastasized breast cancer was 
treated with docetaxel as a second line chemotherapy. Following the third 
cycle she developed some paresthesias in her feet. FolIO\ving the fifth cycle, 
paresthesias in her feet had worsened and she developed numbness in her 
feet and paresthesias in her hands. At examination, loss of vibration and 
position sense at her feet was found. FolIO\ving the next cycle, she noticed 
that anteflexion of her neck greatly increased the paresthesias in her feet. 
NCV studies showed an axonal mixed sensorimotor neuropathy. Because of 
toxicity the treatment was discontinued. Eight weeks later, both sensory 
complaints and LS were improving. Shortly afterwards, she died from 
progression of cancer. 
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Patient D, a 36-year-old woman was treated with docetaxel for bone 
metastasis of breast cancer. Following the third cycle, she developed transient 
paresthesias and numbness of her feet. She also noticed that flexion of the 
neck provoked the paresthesias in her feet. The MRI of the cervical spine 
showed bone metastasis without cord compression, the CSF was normal. 
Vitamin B12 and folic acid were also normal. Following the fourth cycle, 
reflexes were absent but no significant sensory abnormalities were found. 
Following each cycle numbness and paresthesias increased, but improved in 
the days before the next cycle. NCV studies following the sixth cycle showed 
an axonal sensory neuropathy. The neurological examination was unchan-
ged. Following the eighth cycle, the dosage of docetaxel was reduced to 
75mg/m2 per cycle because of leukopenia. With this dosage, the symptoms of 
neuropathy and lS disappeared, and no further episodes of leukopenia occur-
red. 
Patient E, a 69-year-old man, with bladder cancer had developed multiple 
bone metastases and local progression with infiltration into the left 
lumbosacral plexus. He received seven cycles of docetaxel. After four cycles 
he reported mild paraesthesias in his hands, and at examination loss of 
vibratory perception at his toes and loss of tendon reflexes at his legs were 
found. After the seventh cycle progressive neuropathic symptoms, consisting 
of numbness and severe paraesthesias in hands and feet, and difficulty in 
walking, developed. He had noticed tingling in hands and feet with flexion of 
the neck. Despite a partial tumor response, the chemotherapy was 
discontinued. The EMG and nerve conduction studies revealed a severe 
mainly sensory neuropathy. Progression of the tumor was diagnosed three 
months later, thereafter the patient was lost to the follow-up. 
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Discussion 
We descibe five patients who developed LS during the treatment with 
docetaxel. LS has also been described in cisplatin and in pyridoxine induced 
neuropathy I", Similar to these drugs docetaxel may induce a predominantly 
sensOlY axonal neuropathy causing paresthesias and numbness in a stocking-
and-glove-fashion 3,4, Four of the presently reported patients developed a mild 
or moderate sensory neuropathy within three cycles of treatment. This 
suggests they may have been more vulnerable to neurotoxic effects of 
docetaxel than the average patient. Two patients developed LS at the same 
time as the neuropathy, the other three became aware of this phenomenon 
following an additional three cycles, As all patients had a docetaxel induced 
sensory neuropathy, as a discontination of treatment or dose reduction of 
docetaxelled to improvement of both neuropathy and LS, and no other cause 
for LS was found, we presume the LS in these patients was caused by the 
docetaxel chemotherapy, 
We believe LS may not be rare in patients treated with docetaxel. Patients 
A and E were already mentioned in an earlier study on docetaxel induced 
neuropathy in 41 patients 4, The other three patients in this report are from a 
group of 46 patients who were evaluated for the development of neuropathy 
and who had been treated with more than two cycles of docetaxel. Thus, we 
observed LS in five out of 87 patients treated with more than two cycles of 
docetaxel. 
LS is usually considered a symptom of spinal cord involvement, for which 
reason LS in cisplatin neuropathy has been considered as evidence of a toxic 
effect of cisplatin on the spinal cord 5,', However, the different clinical 
presentation of LS in spinal cord lesions due to, for instance, spinal cord 
compression as compared to in cisplatin or docetaxel induced LS, suggests a 
different mechanism in both phenomena, In spinal cord lesions, patients 
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usually report electric shock-like sensations along the spine and legs 
provoked by neck flexion. In cisplatin or docetaxel induced LS neck flexion 
usually provokes paresthesias in feet or legs, and in some cisplatin treated 
patients paresthesias or electric shock sensations can also be elicited by 
I Lasegue's manoeuvre . 
Cisplatin primarily affects the dorsal root ganglia; in experimental 
pyridoxin neuropathy, a low dose of pyrodixin causes an axonal sensolY 
neuropathy, whereas higher doses cause necrosis of the dorsal root ganglia 
with Wallerian degeneration of both peripheral and central sensory neurons 
(in the spinal cord) 5.7. Neurofysiological studies have demonstrated that LS 
reflects an abnormal mechanosensitivity of damaged sensOlY axons in either 
the spinal cord, or the dorsal roots or the dorsal ganglia 8.'. On flexing the 
neck, the spinal canal lengthens which causes stretching of the spinal cord 
and the intrathecal nerve roots. Thus, it is likely that LS in toxic sensory 
neuropathies is due to the stretching of degenerated, abnormally mechano-
sensitive axons in roots and dorsal columns following a lesion of the sensory 
neuron in the dorsal ganglion. This would imply involvement of the sensory 
cell body in patients with docetaxel induced LS. In paclitaxel induced 
neuropathy, both a distal dying back axonopathy and a neuronopathy have 
been postulated as the primary pathological process. This may also depend 
on the dosage of paclitaxel, similar to in experimental pyridoxin neuropathy, 
and on the susceptibility of an individual patient 3.10. As docetaxel and 
paclitaxel neuropathy have a great similarity, these assumptions \vill also 
hold for docetaxel neuropathy. 
In conclusion, docetaxel chemotherapy may cause LS, but if LS develops 
in cancer patients one should always consider the possibility of spinal cord 
compression. 
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Abstract. 
Docetaxel is a new antimicrotubule agelit that induces a predominantly 
sensory neuropathy that is mild in most patients. This prospective study was 
performed to determine if corticosteroid co-medication reduces the 
incidence and severity of Docetaxel-induced neuropathy. 
Two groups of patients treated with Docetaxel in subsequent cohorts 
were prospectively analyzed for neurotoxicity. Group A consisted of 38 
patients with a variety of solid tumors, who were treated in studies before 
corticosteroid co-medication was recommended, while 49 female patients in 
group B with metastatic breast cancer were treated after co-medication with 
corticosteroids was introduced as a routine. Neuropathy was evaluated by a 
clinical sum-score for symptoms and signs and by measurement of the 
Vibration Perception Threshold (VPT). The severity of the neuropathy was 
graded according to National Cancer Institute Common Toxicity Criteria 
(Ncr-CTC). 
In 42% of the patients of group A and in 65% of the patients of group B a 
mainly mild neuropathy was documented. There was no statistically 
significant difference in neurotoxicity between group A and B. The 
cumulative dose of Docetaxel showed a significant correlation with the post-
treatment scores of the VPT, sensory sum-score, grade of paresthesias, and 
grade of neurosensory- and neuromotor toxicity. 
We conclude that corticosteroid co-medication does not reduce the 
development of Docetaxel-related neuropathy. 
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Introduction 
Docetaxel (Taxotere, Rh6ne-Poulenc Rorer, Antony, France) is a new 
semi-synthetic taxoid that is prepared from 10-deacetyl baccatin III, a non-
cytotoxic precursor extracted from the needles of the European Yew, Taxus 
Baccata. Like Paclitaxel (Taxo!), Docetaxel acts as an antimicrotubule agent 
that enhances polymerization of the tubulin into stable micro tubules and 
inhibits microtubule depolymerization. This leads to a disruption of the 
equilibrium within the microtubule system and ultimately to cell death H. 
In phase I studies on the single agent Docetaxel the major dose limiting 
toxicity (DLT) was neutropenia which appeared to be short-lasting, dose-
dependent, schedule-independent and non-cumulative 5 0 10. Based on these 
phase I studies the recommended single agent dose and schedule for 
Docetaxel was 100 mg/m' given as a one hour infusion every 3 weeks. Phase 
II studies on Docetaxel showed activity in breast cancer 11 0 15, non-small cell 
I 16-18 h d d I 19 • 10 I 21 f ung cancer ,ea an nee {cancer ,gastnc cancer ,Ine anOlna , so t 
tissue sarcoma JJ, and pancreatic cancer JJ. The most important side effect 
was an early short-lasting neutropenia which in 20% of the patients was 
complicated by an infection I. Other side effects included alopecia, nausea, 
vomiting, diarrhea, mucositis, asthenia, infrequent hypersensitivity 
reactions, skin reactions, nail changes, fluid retention and a mild sensory 
h 1,2.4-26 neuropat y . 
We prospectively assessed neurotoxicity in 41 patients treated \vith 
Docetaxel as first or second line chemotherapy. Docetaxel induced a 
predominantly sensory neuropathy in 20 out of 41 patients that was mild in 
most patients. However, at cumulative doses above 600 mg/m', 3 out of 15 
patients developed a moderate neuropathy and lout of 15 patients a severe 
one H. Most of these patients did not receive corticosteroid co-medication. In 
the present study we prospectively assessed neurotoxicity in patients with 
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metastatic breast cancer who were treated in a multicentre study of 
Docetaxel, and who routinely received corticosteroid co-medication during 
five days. The results of this prospective study were compared with those of 
the previous study", ,vith the aim to determine if corticosteroid co-
medication reduces andlor delays Docetaxel-induced neurotoxicity. 
Patients and methods 
In two groups of patients with metastatic or locally advanced cancer 
neurotoxicity was assessed prospectively. Group A included patients with 
metastatic or locally advanced cancer who participated in one of four 
different multicentre phase II trials on the activity of Docetaxel as first or 
second line chemotherapy as described before ". The patients with breast 
cancer who were randomized to receive prophylactic corticosteroids were 
excluded from the analyses. Group B consisted of patients with histologically 
or cytologically proven breast cancer who had not responded to conventional 
chemotherapy and participated in a compassionate use programme. 
Eligibility criteria for all studies were: 1) age:20 18 years; 2) WHO 
performance status 0-2; 3) adequate hematological (granulocytes:20 2.0 x 
10'!!), renal (serum creatinine S 1.5 x upper normal limit) and hepatic 
function (total serum bilirubin S 1.25 x upper normal limit); 4) no clinical 
signs of symptomatic peripheral neuropathy grade 2 or more according to 
the National Cancer Institute (NCr) Common Toxicity Criteria (CTC) 27. All 
patients had given informed consent. 
Docetaxel was supplied by Rh6ne-Poulenc Rorer (Antony, France) and 
administered as a one hour infusion at a dose of 100 mg/m' every 3 weeks. In 
six patients of group A the dose per cycle was divided and given on days 1 
and 8 every 3 weeks lll. In group B all patients received co-medication 
consisting of 8 mg of Dexamethasone orally 13 hours, 7 hours, and 1 hour 
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before Docetaxel infusion, followed by Dexamethasone 8 mg orally twice a 
day during 96 hours after Docetaxel administration. In group A no 
corticosteroids were given because these patients were treated in studies 
before corticosteroid co-medication was recommended. No other neurotoxic 
drugs were used during the study or follow-up period. 
The severity of the neuropathy was evaluated by a questionnaire for 
neurological symptoms, by standardized neurological examination and by 
measurements of the Vibration Perception Threshold (VPT) before the start 
of the treatment, after every two cycles, at 2 weeks after the last dose of 
Docetaxel, and every 3 months thereafter. The questionnaire established 
separately absence (0) or presence (1) of paresthesias, numbness, loss of 
dexterity and unsteadiness of gait. On sensOlY examination, position sense, 
vibration sense, pin-prick sensation, Romberg's sign, Romberg's sign with 
heel-to-toe stand and tendon-reflexes of the legs were each scored as normal 
(0) or abnormal (1). A sum-score for these signs and symptoms was calcu-
lated (minimum 0, maximum 11). The severity of paresthesias was graded 
on a 5-point scale (0, no; 1, temporary; 2 continuous & light; 3, severe; 4, 
unbearable). Sensory loss was defined as an abnormal test on either position 
sense, vibration sense or pin-prick sense. Patients were asked whether they 
experienced Lhermitte's sign or pain. The distal muscle strength in the lower 
extremities was tested. Motor signs were defined as the presence of objective 
weakness. The severity of the neuropathy was scored according to the NCI 
Common Toxicity Criteria (CTC) 27 for sensory neuropathy (0, no symptoms 
or signs; 1, mild paresthesias, loss of deep tendon reflexes; 2, moderate 
paresthesias, objective sensory loss; 3, severe paresthesias, sensOlY loss 
interfering \vith function). The VPT was measured at the dorsum of the 
second metacarpal bone of the left hand with a Vibrameter type IV (So medic 
AB, Stockholm, Sweden) and recorded in micrometers of skin displacement. 
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This Vibrameter uses a vibratOlY frequency of 100 Hz and corrects for 
pressure-induced alterations of vibratolY amplitude. The mean value of three 
measurements of the VPT determined with the method of limits was 
considered the actual VPT ". The VPT has been shown to be a reliable 
technique to monitor Cisplatin neuropathy and shows a good correlation 
with the sum-score of neuropathic signs and symptoms as observed 
previously 30.". It has been used to quantify paclitaxel-induced neuropathy". 
For the assessment of neurotoxicity, the post-treatment evaluation on day 
90 was chosen as the primary endpoint, since a relation was suggested 
between Docetaxel-induced toxicity and the cumulative dose. Cycles of 
Docetaxel given after the last neurological evaluation, which occurred in 27 
patients, were not counted in the analysis and excluded from the calculation 
of the cumulative dose. 
Primary endpoints for the analysis were the VPT, the sensory sum-score, 
the grade of paresthesias, the CTC neurosensory grade and the CTC 
neuromotor grade. Because of the skewed distribution of the VPT the natural 
logarithm was used for statistical analysis. The post-treatment grade of 
patients with pre-existing paresthesias, CTC neurosensory or CTC 
neuromotor with grade 2 1, was considered a if it had not increased at post-
treatment evaluation. Analysis of co-variance was applied to test for a 
difference between the two treatment groups in post-treatment sensory sum-
score and log VPT while adjusting for pre-treatment values, age and the 
cumulative dose of Docetaxel (log transformed). Ordinal logistic regression 
analysis, according to the proportional odds model ", was applied to 
compare the two groups with respect to the post-treatment grade of 
paresthesias, neurosensory and neuromotor, adjusted for age and cumulative 
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dose of Docetaxel. The p-values reported in the results section for the 
comparison of groups A and B are all based on these adjusted analyses. 
Results 
A total of 87 patients were evaluable for neurotoxicity. Patient 
characteristics are given in table 7.1. The two groups we studied differed in 
several ways; group A consisted of patients with various tumor types of 
whom nine patients had received Cisplatin as prior antitumor therapy, 
whereas all patients of group B were females with metastatic breast cancer of 
whom most were pretreated with non-neurotoxic chemotherapy. The 
patients with breast cancer in group A did not receive corticosteroid co-
medication. In both groups there was 1 patient with diabetes mellitus and 2 
patients of group A reported alcohol abuse. 
Table 7.2 represents the number of cycles and the cumulative dose of 
Docetaxel administered to both groups. All patients started treatment at a 
dose of 100 mg/m' every three weeks, but in some patients dose reductions 
were required because of various adverse effects. In the six breast cancer 
patients of group A the dose per cycle was divided and given on day 1 and 8 
every three weeks. The cumulative dose of Docetaxel was < 300 mg/m' in 15 
patients of group A and in 10 patients of group B, 300-600 mg/m' in 9 
patients of group A and in 15 patients of group B, and> 600 mg/m' in 14 and 
24 patients of group A and B respectively. 
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Table 7.1 
Patient characteristics 
Group A Group B 
number of patients 38 49 
age median years 52 SO 
(range) (28-73) (31-73) 
sex male/female 15/23 -/49 
WHO performance statl 
0 16 13 
1 19 33 
2 3 3 
prior treatment 
cisplatin 9 1 
vincristine 
other chemotherapy IS 45 
tumor type 
breast 6 49 
ovarian 10 
sarCOlna 7 
bladder 7 
head and neck 5 
melanoma 2 
colorectal 1 
Table 7.2 
Number of cycles and cumulative dose of Docetaxel 
Group A Group B 
number or cycles 
median 4 6 
(range) (2-11) (1-20) 
cumulative dose (mg/m2) 
median 363 575 
(range) (100-1100) (100-1700) 
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Before the start of the treatment four patients in group A and three 
patients in group B showed a mild sensory neuropathy. The four patients in 
group A had been pretreated with Cisplatin. In table 7.3 the increase in the 
sensory sum-score, VPT, paresthesias and grade of neurosensory and 
neuromotor toxicity are shown at the post-treatment evaluation in relation to 
the treatment group. According to eTe criteria 16 patients of group A (42%) 
and 32 patients of group B (65%) developed a sensory neuropathy. There 
was no statistically significant difference between groups A and B in the post-
treatment scores of the VPT (p = 0.87), sensory sum-score (p = 0.83), 
paresthesias (p = 0.62), and eTe neuromotor (p = 0.53). In group B 
somewhat higher eTe neurosensory grades were found compared to group 
A (p = 0.Q4). 
Table 7.3 
Increase in neurotoxicity in relation to treatment group 
Group A Group B 
number of assessable patients 38 49 
sensory sum-score increase 
mean ±SD 2.5 ±2.7 2.7 ±2.2 
VPT ratio post/pre treatment 1.2 ±O.7 1.5 ±O.9 
mean ±SD 
N % N % 
Paraesthesias 
no increase 18 47 28 57 
grade 1 9 24 6 12 
grade 2 9 24 6 12 
grade 3 I 3 7 14 
grade 4 I 3 2 4 
eTC neurosensory 
no increase 22 58 17 35 
grade 1 14 37 21 43 
grade 2 2 5 9 18 
grade 3 0 0 2 4 
eTC neuromotor 
no increase 34 89 42 86 
grade I 3 8 4 8 
grade 2 0 0 3 6 
grade 3 I 3 0 0 
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Table 7.4 
Increase in neurotoxicity in relation to cumulative dose of Docetaxel 
< 300 mg/mt 300.600 mg/m2 > 600 mg/m2 
group A B A B A B 
number of 15 10 9 15 14 24 
palients 
sensory sum-
score 1.2 ±1.1 0.6 ±l.l 2.2 ±2.2 3.3 ±2.4 4.0 ±3.4 3.1 ±1.9 
Increase(l) 
VPT ratio(l) 1.3 ±0.9 1.1 ±0.6 1.0 ±0.2 1.3 ±0.7 1.3 ±0.8 L8±L3 
paraesthesias 
No increase 9 8 4 6 5 
Grade 1 5 1 2 3 2 
Grade 2 1 0 3 3 5 
Grade 3 0 1 0 1 
Grade 4 0 0 0 2 
CTC 
neurosensory(J) 
No increase 13 10 5 2 4 
Grade 1 2 0 4 8 8 
Grade 2 0 0 0 5 2 
Grade 3 0 0 0 0 0 
CTC 
m 
neuromotor 
No increase 15 9 9 13 10 
Grade 1 0 1 0 1 3 
Gmde2 0 0 0 1 0 
Grade 3 0 0 0 0 1 
co Difference between post-treatment and pre-treatment score. Values are means ±SD. 
(1) Ratio oj post-treatment and pre-treatment score. Values are means ±SD. 
14 
2 
3 
5 
0 
5 
13 
4 
2 
20 
2 
2 
0 
{JJ Incidence at post-treatment evaluation; ill case oj pre-existing graded toxicities, only IliglJer 
grades are counted. 
Table 7.4 represents the mean increase in the sensOlY sum-score, the 
mean VPT ratio, the increase in the severity of paresthesias, the CTC-
neurosensOlY grade and the CTC-neuromotor grade at the post-treatment 
evaluation classified by the cumulative dose. At a cumulative dose of 
Docetaxel < 600 mg/m2 six out of 24 patients in group A showed a mild 
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sensory neuropathy, while in group B eight out of 25 patients developed a 
mild sensory neuropathy and five out of 25 patients developed a moderate 
one. At a cumulative dose ~ 600 mg/m2 10 out of 14 patients in group A 
developed a sensolY neuropathy that was mild in eight patients and 
moderate in two patients. In group B 19 out of 24 patients who had received 
a cumulative dose ~ 600 mg/m2 developed a sensory neuropathy that was 
mild in 13 patients, moderate in four patients and severe in two patients. 
Neuromotor toxicity was reported in four patients of group A and in seven 
patients of group B. Neurotoxicity was a reason to stop the Docetaxel 
treatment in three patients (8%) of group A and in six patients (12%) of 
group B. 
The cumulative dose of Docetaxel showed a positive association with all 
post-treatment scores when adjusted for the pretreatment score, age and 
treatment group: VPT (p = 0.02), sensory sum-score (p < 0.00l), grade of 
paresthesias (p = 0.11), eTC neurosensory (p < 0.00l), and eTC 
neuromotor (p = 0.09) 
Discussion 
Docetaxel (Taxotere, Rhone-Poulenc Rorer, Antony, France) is a new 
antimicrotubule agent that has shown activity in a variety of solid tumors II· 
". It induces a frequent dose-dependent, predominantly sensory neuropathy 
that is mild in most patients "'''. New et al " reported a sensorimotor 
neuropathy in 11 % of 186 patients that were treated with Docetaxel at a wide 
range of cumulative doses (50-720 mg/m2) and dose levels 00-115 mg/m2). 
Hilkens et al " documented a sensory neuropathy in 20 (49%) out of 41 
patients that was mild in most patients, but at cumulative doses of Docetaxel 
higher than 600 mg/m2 3 patients developed a moderate neuropathy and 1 
patient a severe one. The clinical characteristics of severe peripheral 
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neuropathy were described in detail ", Disabling and painful paresthesias, 
loss of tendon reflexes, loss of dexterity and steadiness of gait and proximal 
weakness dominated the clinical picture in these patients, In some patients 
Lhermitte's sign was observed ",36, Freilich et al 37 reported a motor 
neuropathy due to the treatment with Docetaxel in 7 out of 60 patients 
(12%), The motor weakness was predominantly proximal; it seemed 
idiosyncratic as it occurred at any stage of treatment and had a variable 
course, The motor neuropathy appeared to be reversible upon the cessation 
of the Docetaxel therapy, 
The present study was performed to determine if corticosteroid co-
medication reduces the incidence and/or severity of Docetaxel-related 
neuropathy, In the early studies on Docetaxel, corticosteroid co-medication 
was not given routinely, However, in a phase II study of the EORTC Breast 
Cancer Study Group in which patients treated with Docetaxel were 
randomized between prophylactic oral antihistamine with or without 
methylprednisolone, corticosteroids appeared to decrease the severity of 
Docetaxel-related fluid retention ", Furthermore, the application of 
corticosteroid co-medication markedly reduced the incidence of 
hypersensitivity reactions induced by Docetaxel ", Considering these 
observations it was recommended to administer corticosteroid co-medication 
routinely in later studies on Docetaxel. 
Hilkens et al performed a prospective study in which patients treated 
with Docetaxel were assessed for neurotoxicity", Most of these patients did 
not receive corticosteroid co-medication, except for some patients with 
breast cancer who participated in a phase II study in which patients were 
randomized to receive pre-medication with or without methylprednisolone 
", In the present analysis we deleted the patients who were randomized to 
receive corticosteroid co-medication (group A) and compared the results of 
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this group with the results of a study that prospectively assessed patients for 
neurotoxicity who were treated with Docetaxel and received corticosteroid 
co-medication (group B). The two groups differed in several ways; the 
patients in group A had a variety of tumor types and 9 out of 38 patients 
were pre-treated with Cisplatin. The patients in group B, however, were all 
females with metastatic breast cancer who were pre-treated with non-
neurotoxic chemotherapy. 
There was no statistically significant difference in the post-treatment 
scores of the VPT (p = 0.87), sensory sum-score (p = 0.83), paresthesias (p = 
0.62), and CTC neuromotor (p = 0.53) when adjusted for the pretreatment 
score, age, treatment group and the cumulative dose of Docetaxel. In group B 
somewhat higher CTC neurosensOlY grades were reported compared to 
group A (p = 0.04). This could be explained by the fact that the median 
number of cycles administered and the cumulative dose of Docetaxel were 
higher in group B than in group A. The cumulative dose of Docetaxel was 
strongly associated with all post-treatment neurotoxicity scores. 
We conclude that corticosteroid co-medication does not reduce the 
incidence or severity of Docetaxel-related neuropathy. Nevertheless there is a 
role for corticosteroids since they do reduce the incidence of hypersensitivity 
reactions and Docetaxel-related fluid retention 
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Abstract 
Docetaxel, a new semi-synthetic taxoid that has demonstrated promising 
activity as an anti-neoplastic agent, was administered in combination with 
cisplatin to 63 patients in a dose-escalating study. As both drugs were known 
to be potentially neurotoxic, peripheral neurotoxicity was prospectively 
assessed in detail. Neuropathy was evaluated by clinical sum-score for signs 
and symptoms and by measurement of the Vibration Perception Threshold 
(VPT). The severity of the neuropathy was graded according to the National 
Cancer Institute's 'Common Toxicity Criteria'. 
The docetaxel-cisplatin combination chemotherapy induced a 
predominantly sensory neuropathy in 29 (53%) out of 55 evaluable patients. 
At cumulative doses of both cisplatin and docetaxel above 200 mg/m', 26 
(74%) out of 35 patients developed a neuropathy which was mild in 15, 
moderate in 10 and severe in one patient. Significant correlations were 
present between both the cumulative dose of docetaxel and cisplatin and the 
post-treatment sum-score of the neuropathy (p < 0.01) as well as the post-
treatment VPT (p < 0.01). The neurotoxic effects of this combination were 
more severe than of either cisplatin or docetaxel as a single agent at 
comparable doses. 
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Introduction 
Docetaxel (Taxotere®) is a new semi-synthetic taxoid that has 
demonstrated substantial clinical activity against a wide variety of solid 
tumors 1-7. Docetaxel inhibits tubulin depolymerization and promotes 
microtubule assembly, resulting in dysfunctional micro tubules I. 
In view of their partly non-overlapping side-effects and their activities in 
a wide range of tumor types, developing combination chemotherapy 
regimens including both taxoids and platins is of major interest 8-10. An 
important dose-dependent side-effect of cisplatin is the development of 
peripheral neuropathy, mainly affecting thick-fiber mediated sensOlY 
qualities n-15. Neuropathy has also been reported as a dose-dependent side-
effect of the treatment with paclitaxel (Taxol®) 16.n. As expected, trials on the 
combination chemotherapy of cisplatin and paclitaxel found a high 
incidence of peripheral neuropathy 8.10. 
Peripheral neurotoxicity has been reported as a frequent, but usually mild 
side-effect of docetaxel in several phase I and phase II studies 2-7.18-21 • The 
neurotoxic effects of docetaxel in a combination chemotherapy with cisplatin 
are unknown. In our institution a phase I trial on the combination of 
docetaxel and cisplatin in metastatic or locally advanced solid tumors was 
conducted n. To study the neurotoxicity of this combination chemotherapy 
we prospectively evaluated all patients participating in this trial by detailed 
neurological examinations. 
Patients and methods 
All participating patients had a metastatic or locally advanced solid tumor 
for which no other appropriate anti-tulllor therapy was available. Other 
inclusion criteria were age 18-75 years, vVHO performance status 0-2, no 
prior treatment with platinum derivates or taxoids, norlllal organ functions, 
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a life expectancy of 3 months or more and written informed consent. 
Patients with a symptomatic peripheral neuropathy grade 1 or more 
according to the "National Cancer Institute (NCI) criteria" (Table 8.1) and 
patients with brain or leptomeningeal metastases were excluded. 
The chemotherapy was administered in 3-weekly regimens. Docetaxel, 
supplied by Rh6ne-Poulenc Rorer, was given as a I-hour infusion. Cisplatin 
was dissolved in 3% saline and administered as a 3-hour infusion with 24 
hours of hyperhydration. In most patients docetaxel was given 3 hours prior 
to cisplatin. In some patients the sequence was reversed and docetaxel was 
given 18 hours following the cisplatin administration. Scheduled dose-
escalation included cisplatin doses of 50, 75 and 100 mg/m' and docetaxel 
doses of 55, 70, 85 and 100 mg/m'. No other neurotoxic drugs were applied 
during the trial or follow-up period. 
Table 8.1 
Severity of paresthesias and 'Common Toxicity Criteria' of the NCI 
PARESTHESIAS 
a = no 
1 = temporary 
2 = continuous & light 
3 = severe 
4 = unbearable 
CTC-NEUROSENSORY 
a = no symptoms or signs 
1 = mild paresthesias, loss of 
deep tendon reflexes 
2 = moderate paresthesias, 
objective sensory loss 
3 = severe paresthesias, sensory 
loss interfering with function 
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The severity of the neuropathy was assessed by a questionnaire for 
neurological symptoms, by standardized neurological examination and by 
measurements of the Vibration Perception Threshold (VPT) before the start 
of the treatment, after each cycle, at 2 weeks after the last dose of docetaxel 
and every 3 months thereafter. The questionnaire established separately 
absence (0) or presence (1) of paresthesias, numbness, loss of dexterity and 
unsteadiness of gait. On sensory examination position sense, vibration sense, 
pin-prick sensation, Romberg's sign, Romberg's sign with heel-to-toe stand 
and tendon-reflexes of the legs were each scored as normal (0) or abnormal 
(1). A sum-score for these signs and symptoms was calculated (minimum 0, 
maximum 11). The severity of the paresthesias was graded on a 5-point scale 
(Table 8.1). Sensory loss was defined as an abnormal test on either position 
sense, or vibration sense or pin-prick sense. Patients were asked whether 
they experienced Lhermitte's sign or pain. The distal muscle strength in the 
lower extremities was tested. Motor signs were defined as the presence of 
objective weakness. The severity of the neuropathy was scored according to 
the NCI Common Toxicity Criteria (CTC) for sensory neuropathy (Table 
8.1). The VPT was measured at the dorsum of the second metacarpal bone of 
the left hand with a Vibrameter type IV (Somedic AB, Stockholm, Sweden) 
and recorded in micrometers (!-1m) of skin displacement. This Vibrameter 
uses a vibratory frequency of 100 Hz and corrects for pressure-indnced 
alterations of vibratory amplitude. The method of limits was used to obtain 
the mean VPT and this was repeated three times ". The VPT has been shown 
to be a reliable technique to monitor cisplatin neuropathy and shows a good 
correlation \vith the sum-score of neuropathic signs and symptoms as 
observed previously n". It has been applied to quantify paclitaxel-induced 
h 17 neuropat y . 
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In some patients electrophysiological studies were done before and after 
the treatment. The distal latency and nerve conduction velocity (NCV) of the 
ulnar (sensory and motor), peroneal (motor) and sural nerve, the compound 
motor action potential (CMAP) of the ulnar and peroneal nerve and the 
sensory nerve action potential (SNAP) of the ulnar and sural nerve were 
determined. A 50% decrease in CMAP and SNAP amplitude and a 15% 
decrease of NCV were considered abnormal. 
The first post-treatment evaluation was used as a primary endpoint for 
the assessment of neurotoxicity. Cycles of docetaxel and cisplatin given after 
the last neurological evaluation, which occurred in eight patients, were not 
counted in the analysis and exCluded from the calculation of the cumnlative 
dose. 
A subdivision was made into three groups according to the cumulative 
dose of cisplatin and docetaxel. The mean increase in the sum-score and the 
ratio of VPT post-treatment with respect to the VPT pre-treatment (VPT 
post/pre ratio) within groups were calculated. A comparison of the severity 
of neuropathy in relation to cumulative dose was made with two other 
prospective trials performed in our institution in the same period ".21• In 
these trials cisplatin and docetaxel were studied as single chemotherapeutic 
agents and identical methods for the measurement of neuropathy were 
applied as described here. 
The incidence of neurological signs and symptoms at the first evaluation 
after the last cycle was determined. Patients with pre-existing signs or 
symptoms were not included in these calculations. Graded paresthesias pre-
treatment were included only if there was an increase in the grade of 
paresthesias post-treatment. The change in the sensory sum-score and the 
VPT post/pre ratio were calculated for each patient. Spearman rank-
correlations were calculated to describe the strength of the association 
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between cumulative doses of cisplatin and docetaxel and the increase in the 
sensory sum-score and the VPT post/pre ratio. Because of the skewed 
distribution of the VPT the geometric mean was used to determine the mean 
of the VPT post/pre ratio. For the sensory sum-score the arithmetic mean 
was calculated. 
Results 
Sixty-three patients were entered into the trial. Eight of these 63 patients 
were excluded from the assessment of neurotoxicity because a pre-treatment 
evaluation was lacking. Patient characteristics, tumor-type and previous 
chemotherapy of 55 patients evaluable for the present analysis are shown in 
table 8.2. Twenty-seven patients had previously been treated with non-
neurotoxic chemotherapy. One patient had been treated with vincristine. 
None of the patients had received a prior treatment with cisplatin. Five 
patients had diabetes mellitus and 5 patients reported alcohol abuse. 
Twenty patients received 1-2 cycles, 6 patients 3-4 cycles, 28 patients 5-6 
cycles and 1 patient 8 cycles before their last evaluation. Per cycle the mean 
dose of cisplatin was 74 mg/m' (range 50 -100 mg/m') and of docetaxel 
82 mg/m' (range 38-100). The mean cumulative dose given of cisplatin was 
297 mg/m' (range 75-600 mg/m') and ofdocetaxel 326 mg/m' (range 75-600 
mg/m'). The mean duration of the follow-up after the last cycle was 96 days 
(range 7-315 days) 
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Table 8.2 
Patient characteristics and tumor type 
number of evaluable patients 
sex male/female 
age 
tumor type 
prior therapy 
mean (yrs) 
(range) 
colorectal 
ACUpl 
breast 
head and neck 
sarCOlna 
melanoma 
NSCLC' 
miscellaneous 
cisplatin 
vincristine 
other chemotherapy 
') Adenocarcinoma of IInhnown prima1Y 
') NOli-small celllullg carcilloma 
55 
26/29 
53 
(21-74) 
23 
14 
5 
3 
2 
2 
2 
4 
1 
27 
Table 8.3 shows the incidence of neuropathic signs and symptoms at the 
first post-treatment evaluation. Paresthesias were seen in 24 patients (44%): 
in both hands and feet (n~18) or in the feet only (n~6). Three patients 
suffered from pain in either hands or feet, which was felt to be secondary to 
the neuropathy. 
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Table S.3 
Neuropathic signs and symptoms at first 
post-treatment evaluation 
N (%) 
paresthesias 24/55 (44) 
grade 1 S' 
grade 2 9' 
grade 3 53 
grade 4 2 
pain 3/54' (6) 
numbness 17/53 (32) 
loss of dexterity 14/53 (26) 
unsteadiness of gait 9/53 (17) 
Lhermitte's sign 7/54 (13) 
sensory loss 19/46 (41) 
motor signs 9/54 (17) 
Romberg's sign 2/51 (4) 
loss of knee jerks 23/55 (42) 
loss of ankle jerks 29/45 (64) 
1) Excluding one patient with pre-existing paresthesias grade 1 
2) Including one patient with pre-existing paresthesias grade 1 
J) Including one patient with pre-existing paresthesias grade 2 
') Patiellts with these siglls or symptoms at the pre-treatmellt evaluatioll or with missillg data 
were excluded 
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Table 8.4 
Severity of neuropathy in relation to cumulative dose of docetaxel 
and cisplatin 
Cisplatin < 200 mg/m 
, 
200-400 mg/m 
, 
>400 mg/m 
Docetaxel < 200 mg/m 
, 
> 200 mg/m 
, 
>200 mg/m 
N =20 N = 16 N = 19 
sensOlY sum-score 1.1±1.2 4.3 ±2.4 3.5 ±2.9 
increase 1 
mean (±SD) 
VPT post/pre ratio' 1.2 ±0.7 1.9 ±0.9 4.3 ±4.0 
mean (±SD) 
paresthesias 3 
grade 1 1(1)' 2(2) 5(3) 
grade 2 1(1) 5(4) 3(7) 
grade 3 2(3) 3(3) 
grade 4 2(2) -(1) 
CTC neurosensory 3 
grade 1 3(2) 7(7) 8(10) 
grade 2 -(1) 5(4) 5(3) 
grade 3 -(1) 1(3) 
I) difference between the first post-treatment and tlte pre-treatment score. 
') difference between tlte first post-treatment and tlte pre-treatment score, divided by tlte pre-
treatment score (post/pre ratio). 
J) incidence at the first post-treatment evaluation. 
4) = lIumbers wilen lJuLximwn scores post-treatment arc considered. 
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Table 8.4 shows the mean increase in the sensory sum-score, the mean 
VPT post/pre ratio, the severity of paresthesias and the CTC-neurosensory-
grade at the first post-treatment evaluation classified by a cumulative dose of 
docetaxel and cisplatin. According to the CTC criteria, 29 patients developed 
a sensory neuropathy. In the group with a cumulative dose of both cisplatin 
and docetaxel below 200 mg/m' three out of 20 patients showed a mild 
seusory neuropathy (grade O. Out of 16 patients treated with a cumulative 
dose of docetaxel above 200 mg/m' and of cisplatin between 200 and 400 
mg/m', 12 patients developed a sensory neuropathy which was mild in seven 
patients (grade 1) and moderate in five patients (grade 2). In the group with 
a cumulative dose of cisplatin above 400 mg/m' and docetaxel above 200 
mg/m', 14 out of 19 patients developed a sensory neuropathy, grade 1 in 
eight, grade 2 in five, and grade 3 in one patient. In four patients the 
treatment had to be discontinued because of neurotoxicity. 
Twenty-three patients had two or more post-treatment evaluations. Two 
of these patients developed a mild neuropathy (grade 1) during the follow-
up. In four patients the neuropathy further deteriorated during follow-up: 
one patient developed a moderate neuropathy (grade 2) and three patients a 
severe (grade 3) one. 
In 43 patients the sequence of the administration was docetaxel prior to 
cisplatin and in 12 patients vice versa. There was no difference in the 
severity of neurotoxicity as measured with the sensory sum-scores between 
these two different regimens. 
We found a clear correlation between the increase in the VPT and the 
increase in the sum-score (R, = 0.34, P = 0.02) following treatment. The 
cumulative dose of both docetaxel and cisplatin showed a statistically 
significant correlation with the increase in the sum-score (R, = 0.44 and 0.39 
respectively, p < 0.01) and the change in the VPT (R, = 0.68 and 0.65 
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respectively, p < 0.00l). Figure 8.1 shows the VPT post/pre ratio in relation 
to the cumulative dose of docetaxel and cisplatin. Figure 8.2 shows the 
relation of the cUlllulative doses of these drugs and the change in the sensory 
sunl-score. 
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Figure 8.1 
The mean change (± Sf) in vibrationl'erception threshold (VPT) post-treatment in relation to 
the cumulative dose oj docetaxel and cisplatin (mgtm'). The Jigures above the horizontal axis 
indicate the number oJl'atients evaluated and the mean dose oj cisplatin (CP) and docetaxel 
(DOC) in each dose subgroup. 
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Electrophysiological studies before and after the treatment were done in 
26 patients. It showed a decrease in SNAP amplitudes in 15 patients, a 
decrease in CMAP amplitudes in one patient and a decrease in both SNAP 
and CMAP amplitudes in four patients. The NCV studies were unchanged in 
six patients most of whom had been treated with low cumulative doses of 
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both cisplatin and docetaxel. The cumulative dose in the four patients with 
both motor and sensory involvement was similar to the cumulative dose in 
patients with only sensory involvement. 
Table 8.5 shows a comparison of the severity of the neuropathy in 
relation to the cumulative dose of docetaxel between patients in the 
combination chemotherapy trial and patients treated with docetaxel only in 
another prospective trial conducted in our institutionll • At low cumulative 
doses of docetaxel (and consequently also low doses of cisplatin in the 
combination chemotherapy trial) there is a low incidence of nemopathy in 
both trials. When patients with cumulative doses of docetaxel above 300 
mg/m2 are considered, a higher incidence and a more severe neuropathy is 
found in patients treated with the combination chemotherapy in comparison 
with the patients treated with docetaxel only. Figme 8.3 compares the 
relative change in VPT and the change in sensory sum-score in relation to 
the cumulative dose of cisplatin between patients from this trial and patients 
treated with cisplatin only 15. It shows a more severe neuropathy in the 
patients treated with the combination chemotherapy regimen, especially at 
higher cumulative doses of cisplatin. 
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') 
') 
') 
Table 8.5 
Comparison of the severity of the neuropathy between patients treated with 
only docetaxel 21 and patients treated with a docetaxel-cisplatin combination 
chemotherapy, in relation to the cumulative dose of docetaxel 
Docetaxel <300 mg/m 
, 
Docetaxel 300-600 mg/m 
without with without with 
Cisplatin Cisplatin Cisplatin Cisplatin 
N 14 24 12 31 
cum. dose cisplatin 157 ±65 406 ±1l0 
mean (±SD) 
sensory sum-score 1.5±1.2 1.5±1.7 2.9 ±2.5 3.9 ±2.7 
increase 1 
mean (±SD) 
VPT post/pre ratio' 1.4 ±0.9 1.2 ±0.7 1.1 ±0.4 3.3 ±2.7 
mean (±SD) 
paresthesias 3 (50%) (65%) 
grade 1 5 1 3 7 
grade2 1 1 3 8 
grade 3 1 4 
grade 4 1 1 
CTC neurosensory 3 (58%) (77%) 
grade 1 2 3 7 15 
grade 2 2 8 
grade 3 1 
difference between tile firs·t post-treatment and the pre-treatment score. 
difference between the first post-treatment and the pre-treatment score, divided by the prc-
treatment score (pre/post ratio) 
incidencc at the first post-treatmcnt evaluation 
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Figure S.3 
The mean change (± SE) in vibration perception threshold (VPT) and sensory sum~sco,.e post-
treatment in relation to the cumulative dose of cisplatin (mg/m2). Triangles indicate patients 
treated with the docet(l'(el~cisplatin combination c1Jemotherapy and circles indicate patients 
treated with ollly cisplatin 15. The figures indicate the number oj patients evaluated. 
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Discussion 
In recent years docetaxel appeared to be one of the most active new anti-
neoplastic agents. Peripheral neuropathy is one of the potentially dose-
limiting side-effects. In several phase II trials on docetaxel a mild to 
d . I h b d 2-7.20.'1.27 I d f 41 mo erate mam y sensory neuropat y was 0 serve . n a stu y 0 
patients treated with the single agent docetaxel (100 mg/m' every three 
weeks; cumulative doses of 200-ll00 mg/m') 49% of the patients developed 
a usually mild neuropathy 'I. The neuropathy appeared to be dose-dependent 
and caused a severe and disabling neuropathy in some patients at higher 
dose levels. Severe motor involvement occurred in two of these patients. 
In trials on a combination chemotherapy of cisplatin with another taxoid, 
paclitaxel, a high incidence of neuropathy was found. In a phase I study of 
paclitaxel (llO-200 mg/m' per cycle) and cisplatin (50-75 mg/m' per cycle) 
in 44 patients (median no. of cycles 3; range 1-12), 27% developed a mild to 
moderate neuropathy 10. The incidence of neuropathy was disproportionately 
higher than expected with either paclitaxel or cisplatin at comparable single 
and cumulative doses. In a study of 32 patients treated with higher doses of 
paclitaxel (135-350 mg/m' per cycle) and cisplatin (75-100 mg/m' per cycle) 
75% developed a neuropathy 8. It was suggested that the neuropathy was 
mainly due to paclitaxel. The severity of the neuropathy was related to both 
the cumulative and single dose of paclitaxel and the presence of a pre-
existing medical disorder associated with neuropathy (diabetes,alcoholism). 
The neuropathy was of an axonal nature with predominantly sensory signs 
although electrophysiological studies established involvement of motor 
nerves as well '. 
To date there are no results of studies on docetaxel-cisplatin combination 
chemotherapy regimens. In the present study we observed that 53% of the 
patients treated with docetaxel and cisplatin, in a wide range of cumulative 
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doses, developed a mainly sensOlY neuropathy. When only patients with 
cumulative doses of docetaxel and cisplatin above 200 mg/m2 were 
considered, 71% developed a neuropathy. At higher dose levels some 
patients showed a moderate or severe neuropathy. Nine of these patients had 
motor signs. In five out of 26 patients in whom neurophysiological studies 
were performed motor involvement was found. Neuropathy was the dose 
limiting side-effect in four patients. 
We were able to compare the results of this trial with two other trials 
performed in our institution in which patients were treated with either 
docetaxel or cisplatin as single a agent 1'.21. As expected the combination of 
these two neurotoxic agents tends to induce a more severe neuropathy than 
either of the two drugs alone. However, since these single and combination 
chemotherapy schedules were not studied in a comparative trial, this should 
be interpreted with caution. As the cumulative dose of cisplatin and the 
cumulative dose of docetaxel were closely related in our study, we could not 
detect which drug accounted for most of the neuropathy. A synergistic effect 
of the two drugs cannot be excluded. 
The value of the VPT as a sensitive indicator of neuropathy in this study 
is not unequivocal. Several reports have demonstrated that the VPT is a 
reliable measure of cisplatin neuropathy 24.". In a previous study we did not 
establish a significant relation between the VPT and the severity of 
docetaxel-induced neuropathy, possibly because small fibre functions are 
compromised in this neuropathy 21. The change in the VPT in this study can 
probably be accounted for by cisplatin, that mainly affects large myelinated 
fibres. 
In a phase I study on a paclitaxel-cisplatin combination chemotherapy it 
was suggested that the sequence of cisplatin administration before paclitaxel 
may be related to more profound neutropenia 10. We were unable to detect 
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differences in the severity of neurotoxicity in relation to the sequence of 
administration of cisplatin and docetaxel. Since only 12 patients received 
cisplatin prior to docetaxel no firm conclusions can be drawn, 
In conclusion: the combination chemotherapy of docetaxel and cisplatin 
induces a dose-dependent sensory neuropathy, At a higher dose range 
neuropathy is encountered in a relatively high proportion of patients, With 
cumulative doses of both cisplatin and docetaxel between 200 and 600 
mg/m' one-third of the patients developed a moderate or severe neuropathy, 
The severity of the neuropathy is higher than with the use of either cisplatin 
or docetaxel as a single agent at comparable doses, Further study on the 
possible attenuating effects of neuroprotective agents such as WR-2721 
( 'f ' ) 28-30 I h' 31,32 d h r 33,34 , d amI ostme , g utat IOn an nerve growt .actor IS warrante , 
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Chapter 9: MetllOds for Assessment of Chemotherapy-indtlced Netlropathy 
Abstract 
Peripheral neuropathy is frequently observed in patients treated with the 
chemotherapeutic agents cisplatiu, vincristine or taxoids. Several clinical 
scales for the grading of chemotherapy-induced peripheral neuropathy have 
been developed, but none of these scales have been validated or 
standardized. 
vVe report on our experience with a neurotoxicity assessment protocol in 
a group of 298 cancer patients who participated in prospective trials in 
which the potential neurotoxicity of several chemotherapeutical agents was 
investigated, and in a control group of 55 healthy subjects. This protocol 
includes the standard assessment of neurological signs and symptoms 
including an ii-point sum-score, quantitative measurement of the vibration 
perception threshold (VPT) and grading according to the "common toxicity 
criteria" (CTC). We determined the following biometric properties of these 
tests: l)the relation between VPT, age and sex 2)the intra-patient variability 
of signs and symptoms 3)the correlation between the different parts of the 
neurotoxicity assessment protocol. 
The normal valnes for the VPT and the relation to age were similar as 
found in previous studies, and the intra-subject variability was acceptably 
low (coefficient of variation 25%). The VPT was related to values of the sum-
score (r ~ 0.54; p < 0.00l) and the CTC grade (r ~ 0.56; P < 0.00l). We 
found only a small variability for most sum-score items of intra-patient 
measurement (0.5-10.5%). Some items of the sum-score become abnormal at 
an early stage (e.g. paraesthesias, sRomberg, ATR), other items at a later one 
(e.g. Romberg's sign, pin-prick and position sense). There was a Significant 
variation in the outcome of the sum-score as compared to the CTC score. 
We conclude that our protocol appears to be a feasible method for the 
assessment of chemotherapy-induced neuropathy in large groups of patients. 
149 
Chapter 9: Methods for Assessment of Chemotherapy-induced Neuropathy 
For individual patients the utility of a grading scale depeuds ou whether this 
scale would indicate the degree of disability, handicap and quality of life. 
Further prospective study, therefore, is necessary to better define a 
standardized and validated neurotoxicity assessment protocol that can be 
used in clinical trials as well as in individual patients. 
Introdnction 
The assessment of chemotherapy-induced toxicity is an important part in 
the evaluation of treatment regimens in cancer. A number of scales and 
protocols have been developed to improve the reporting of toxic effectsl -3 • 
Peripheral neuropathy is frequently observed in patients treated with the 
commonly used anti-neoplastic agents cisplatin, vincristine or taxoids. The 
clinical severity may range from the presence of paraesthesias and some loss 
of sensOlY function to disabling symptoms including neuropathic pain, 
sensory ataxia, motor weakness or autonomic dysfunction 4. An accurate 
diagnosis and grading of the severity of the chemotherapy-induced 
neuropathy are crucial for a proper assessment of the neurotoxicity of these 
and future drugs. 
In most studies grading scales based on the information from the clinical 
history and the neurological examination have been used (Table 9.1(3.'~. In 
addition methods of quantitative sensory testing (QST) have been applied as 
an objective measure for the severity of the neuropathy'-I3. Some authors 
advocate the use of a calculated neurotoxicity sum-score based on changes in 
symptoms, signs, QST and nerve conduction studies14·". None of these scales 
have been validated nor have they been studied on their association with the 
degree of disability, handicap or quality of life. 
In our institution a large number of clinical trials on chemotherapeutic 
drugs are carried out on ongoing basis, testing new agents or schedules. In 
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some of these trials, an extensive assessment of neurotoxicity using a 
standardized protocol has been applied on patients participating in stndies 
with potentially nenrotoxic drugs. Here, we report on the analysis of the 
results from 1050 test-procedures in 353 subjects in order to determine the 
biometric properties of each of the elements of our neuropathy assessment 
protocol. 
Table 9.1 
Grading scales for sympLoms and signs used for the assessment of severity of chemotherapy-induced 
sensory neuropathy 
Common [o!<icitr 
crileria(NO) 
W1I0 critelU' 
Nonhnn OHrernia 
Oncok'gy group' 
Grunb.:rg' 
Castdbnos' 
Ajani' 
gr~de 1 grade 2 
mild plrtsthesm, 10'-5 of __ mild or mooerlle objective 
DTR sCI150ry 1055, moderate 
plrti\hesiIs 
l:tlreSlhcsi.Js andlor st'-ere paresthesi.» 
decreased DrR 
mild pain Or moderate pain, plltithtiilS 
Plltithe.sus 
numbness or tingling 
fingers or toes 
plr.:..sthesu> andlor 
decrcJ.Scd DTR 
(uresthcsm, dccrc"-SCd 
om 
numbness or tingling in hands or 
fut 
mild obje<;live SCIl501Y 
abnorrru!itks andlor absent OTR 
mild obJecth-e abnorm;liity, 
absence of DTR, mild to 
modeme functional abnonnality 
Eastern Cooper.l.ti.-e mild p.lusthesils, senre plTe51he5ias, absent DTR 
Oncology glOup' denused DTR 
acro-pJraesthesl.ls, 
drSlesthesia Olr seILS1Uon 
of ,w"llen lllnds 
DTR ~ distal tendon reflexes 
Methods 
pna"-'thesi.l5 in hJnds or feet, 
reduc(d or absent ~ibrator)' 
S<'-I!51110n and OTR, subjec{I\-( 
clumsiness Olf fine mo'-~ment5 or 
galt 
grade 3 
sewre objulh-e sensory loss 
or paresthesb5 thl! Interfere 
\\ith function 
intolerable plresthesils 
severe pain, plresthesils 
dumsiness fine movemenl5 
senre par"-'lh"-'ias with 
moderate objecti'-e seruor)' 
abnorrruliUes 
se.-eu PJr"-'lhesm, 
moderate objecU'-e 
abnonnllit)', seyeu 
functiolUl abnonnllity 
dis,;tblingserumy loss, 
se'-ere pain 
sensory comphlnl5 refuud 
to as troublesome or painful 
or extended plOximllly, 
absent \ibralOr), sensation 
and DJR. obje~an 
clumsine..>s of fine 
mm-emenl5,Rombi:rg+ 
grade 4 
difficultyarnbulllion 
complete loss of sensalion 
complete :5<'-ruol)'lo:55, 
10:55 of function 
$eMOry complainl5 
troublesome <lr unocara-
ble, absent \ibrJtor), 
sensation Jnd DTR, disul 
h)l'aestesb5, Juxia, fine 
mo,"emenl, possible 
under \uu\ control 
In the Daniel den Hoed Cancer Centre in The Netherlands, a 
standardized protocol has been developed for the assessment of peripheral 
neurotoxicity in patients participating in prospective trials on the efficacy of 
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chemotherapeutic agents in cancer. The requirements for neurotoxicity 
assessment include time-efficiency and reliability with as little of 
inconvenience for the patient as possible, in order to facilitate frequent and 
repetitive testing on an out-patient basis. The focus of the test battery is 
aimed at the scoring of the sensory signs and symptoms, since many of the 
initial trials included cisplatin, which induces a purely sensory neuropathy. 
This protocol has been in use for several years now. 
The neurotoxicity test battery includes a questionnaire for neurological 
symptoms, a standardized neurological examination for sensory and motor 
signs and the measurement of the vibration perception threshold (VPT). 
Patients are tested before initiation of the therapy and at regular intervals 
during and after the period of administering chemotherapy. 
Assessment of neuropathic signs and symptoms 
The questionnaire establishes the presence of paresthesias or numbness 
in hands or feet, loss of dexterity and unsteadiness of gait. The absence of 
each symptom is scored 0, its presence is scored 1. The severity of the 
paresthesias is graded on a 5-point scale (0 = no, 1 = temporaty, 2 = 
continuous & light, 3 = severe, 4 = unbearable). Patients are asked whether 
they experience Lhermitte's sign or pain. On standardized neurological 
examination of the sensory system position sense, vibration sense, pin-prick 
sensation at the great toe, Romberg's sign, Romberg's sign with heel-to-toe 
stand (sensitized Romberg = sRomberg) and knee- and ankle-tendon-reflexes 
of both legs are each scored as either normal(O) or abnol'lnal(l). The muscle 
strength in the lower extremities is tested by standing on the heels and the 
two-step test (testing the ability of stepping two steps for both legs 
separately). A sum-score for the severity of the neuropathy is calculated by 
connting the scores for normal(O) and abnormal(l) signs and symptoms 
(minimum 0, maximum 11). In a later stage we add the scoring of the 
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severity of neuropathy according to the Ncr Common Toxicity Criteria 
(CTC) for sensOlY neuropathy (Table 9.1). 
Vibration perception threshold 
The VPT is measured at the dorsum of the second metacarpal bone of the 
left hand. Patients are sitting in a quiet room with their left hand resting on a 
table. We use a Vibrameter Type III and later Type IV (So medic AB, Stock-
holm, Sweden), a hand-held instrument that applies a vibration stimulus 
with a frequency of 100 Hz by means of a rod with a diameter of l3mm. The 
rod is positioned at the middle of the second metacarpal bone. Adjustment of 
application pressure can be visually controlled during measurement. By 
means of a transducer in the stimulator, the vibration amplitude is measured 
directly at the stimulation site, which eliminates the variable damping effect 
of underlying tissues, and is presented in the actual displacement of the skin 
in micrometers (11m) on a calibrated digital display. Patients are first 
familiarized with the vibratory sensation of the Vibrameter. We use the 
method of limits as described by Goldberg and Lindblom!': increasing the 
stimulus strength from zero to the point where the Vibratory sensation is first 
perceived, and then decreasing the stimulus strength from a slightly 
supramaximallevel to the point where the sensation disappears; the average 
of these two values is taken as the actual VPT. We perform three 
measurements on each assessment and the mean of these measurements is 
being considered to represent the VPT. We perform measurements only on 
one hand as Elderson reported no difference in the VPT measurement of 
either hands or feet in patients with cisplatin neuropathy'. 
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Subjects 
Measurements according to the test-protocol were performed for 55 
healthy control subjects and 298 patients. In order to study the intra-subject 
variability 51 of the 55 controls (25 males, 30 females; median age 41 yrs, 
range 19-70 yrs) were measured on two separate occasions with a median 
interval of 91 days (range 8-612 days). All measurements in control subjects 
were done by one of two investigators(PH,VvR). 
The 298 patients (180 males, ll8 females; median age 53, range 21-76 
yrs) were enrolled in a total of seven trials in the period 1990-1995, which 
studied the neuropathic effects of cisplatin, docetaxel (Taxotere ®) or the 
combination of these drugs. All patients with at least two neurological 
assessments were included in this study. Most patients (n=269) had 
undergone one pre-treatment evaluation, while 29 patients had had no pre-
treatment evaluation. The 944 patient evaluations were carried out by seven 
different investigators. 
Analysis 
The following biometric properties of the tests were studied. 
1. The relation between the VPT, age and sex, restricted to the scores of the 
control subjects and to the pre-treatment scores of the patients and the 
intra-subject variability of the VPT. 
2. The intra-patient variability of all signs and symptoms scored in the period 
from the 
pre-treatment till the end of the treatment and in the period thereafter. 
3. The correlation between the different measurements. 
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Ad 1. 
Because of the skewed distribution of the VPT, the natural logarithm was 
used for statistical analysis. The means and standard deviation of VPT are 
reported in original units, but are derived from the mean and standard 
deviation of 10gCVPT) by back transformation. The relation between the 
logarithm of the VPT with age and sex was determined by linear regression 
analysis. The VPT values of the control subjects \vith two measurements 
counted half in this analysis. Repeated VPT measurements in the control 
subjects were used to estimate the intra-subject variability in the VPT 
assessment. Under the assumption that the size of the measurement errors is 
proportional to the true value of the VPT, the intra-subject variability in the 
VPT is best expressed by the coefficient of variation C CV). The CV was 
derived by the following formula: CV ~ ,ICLOu - 1'1 )' 12.N) where I, and I, are 
the natural logarithm of the first and second assessment of the VPT, and L 
indicates summation over the N~51 control subjects \vith two VPT 
measurements. 
Ad2. 
In the analysis of dichotomous signs and symptoms, scored as normal or 
abnormal, the question mises how to express the intra-patient variability of 
these scores. The score of a subject at a certain time depends on a 'true' 
underlying condition of the subject at that time, but is also dependent on 
supposedly random day-to-day fluctuations and on measurement errors. In 
the assessment of the neurotoxic effect of chemotherapeutic agents, one is 
mainly interested in the change of the true underlying condition i.e. the 
peripheral nerve function and not in random day-to-day fluctuations. When 
the true underlying condition does not change, as may be assumed for 
control subjects, the intra-patient variability of a score can be expressed by 
the fraction of paired observations with different scores. However, especially 
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for patients under or after treatment the true condition may not be constant 
over time. A change of a sign-symptom score from normal to abnormal may 
be compatible with an effect of the treatment. In the period after the 
treatment abnormalities that have appeared during the treatment may resolve 
over time. 
The following measures for intra-patient variability were calculated for 
each sign or symptom. For the control subjects the percentage of patients 
with a different score on the two different occasions was used. For the 
patients the sequence of measurements of each sign and symptom was 
divided in two periods. Period A was defined as the period from pre-
treatment until the first abnormal score post-treatment. Period B was defined 
as the period after period A. Note that period B starts with an abnormal score. 
If there are no observations or no abnormal scores post-treatment, period B is 
empty. For both periods only the data of patients with at least two 
measurements of signs or symptoms in that period were used. The data of all 
pairs of subsequent measurements of all patients were pooled for each period 
and frequencies N'J were calculated. N'J' with i and j equal to 0 or 1, stands for 
the number of pairs of scores (i,j), 0 for normal and 1 for abnormal. From 
the N'J the following measures of fluctuation were calculated: 
FOl~NOl!(NOl+Noo+NIl+NIO) and FIO~N,,/(NIO+NIl+Noo+No). FOI measures how 
often a normal score changes into an abnormal score, while FlO measures how 
often an abnormal score changes into a normal score. FlO is a relevant 
measure for fluctuations in period A, in which one would not expect 
improvements, while FO! is a relevant measure for period B. These measures 
serve primarily as a method to compare the signs and symptoms with one 
another and cannot be interpreted in an absolute sense. 
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Ad3. 
The correlation between the different signs or symptoms scores and VPT 
was studied by calculating for each item the proportion of remaining items 
with abnormal scores and the mean VPT, separately for observations scoring 
either normal or abnormal. 
In addition to this analysis of the biometric properties of the test-protocol, 
we studied the relatiouship between the eTC grading system for sensory 
neuropathy with the sum-score and VPT. 
Results 
Measurements on control subjects. 
* Vibration perception threshold 
With a linear regression analysis of 10g(VPT) on age, the following 
models are fitted for male and female control subjects. 
IOlog(VPT) = -0.66 (±0.09) + O.OlD (±0.002)*age (males) 
IOlog(VPT) = -0.61 (±0.05) + 0.007 (±O.OOl)*age (females) 
Within brackets the standard errors of the estimates are shown. The 
difference in the regression lines between male and female patients is 
statistically significant (P=0.0008). These models explain 36 percent of the 
variance in the 10g(VPT) between subjects as due to the variation in age, both 
in males and females. 
The coefficient of variation of the VPT is calculated from the repeated 
measurements of the control subjects and estimated to be 25%. Standardized 
VPT values, adjusted for age and sex, are calculated as the ratio of the' 
observed VPT and the expected VPT as derived from the fitted regression 
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model. The variation between subjects in the VPT is found to be 37% (47% 
for males and 28% for females). 
* Signs and symptoms 
Most of the signs and symptoms are scored normal for healthy control 
subjects on both occasions. Exceptions are paraesthesias (7% abnormal), 
numbness(1 %), vibration sense (12%), Romberg(1 %), sRomberg (16%) and 
ankle tendon reflex (4%) (Table 2). Different scores on the two occasions are 
observed for numbness (1/51), vibration sense (3/51) and sRomberg (6/51). 
Measurements on patients 
With the exception of sRomberg, ankle tendon reflexes (ATR) and 
vibration perception sense, before treatment abnormal signs and symptoms 
were rare though slightly more frequent than in controls (Table 9.2). The 
VPT pre-treatment for male patients is similar to the values in controls. For 
female patients, however, the pre-treatment values of the VPT are higher 
than those for controls and show a larger variation. During and post-
treatment the percentage abnormalities of all items and VPT increased. At 
that time paraesthesias, sRomberg and ATR are the most frequent 
abnormalities. 
158 
Chapter 9: Methods Jar Assessmellt oj Chemotherapy-illduced Neuropathy 
Table 9.2 
Percentage of abnormal scored items in 55 healty subjects and in 298 
cancer patients with 270 measurements at pre-treatment evaluation and 
664 measurements in these patients during treatment or post-treatment. 
controls pre-treatment durlng- or post treatment 
number of subjects 
number of observations 
pamesthesias 
numbness 
loss dexterit}' 
unsteadiness gait 
position sense 
vibration sense 
pin-prick sense 
Romberg 
sRomberg 
knee tenclon reflex 
ankle tendon reflex 
% of abnonnal items 
mean (±SD) 
VPT (mean ±SD) 
standardized (% ±SD)1 
males 
females 
55 
106 
% abnonnal 
7 
0 
0 
0 
12 
0 
16 
0 
4 
4% (±7) 
0.53 ±O.25 
IOO±45 
100 ±28 
269 
270 
% abnonnal 
5 
3 
2 
2 
3 
12 
3 
3 
42 
2 
18 
8% (±1O) 
0.76 ±0.44 
96±49 
134 ±80 
298 
66. 
% abnonnal 
38 
26 
17 
13 
II 
31 
7 
8 
57 
28 
53 
25% (±23) 
1.28 :!:1.01 
168 ±121 
210 ±155 
, Stalldardized VPT score deJilled as the ratio oJVPT alld the expected value 011 the basis oj age 
and sex. 
sRomberg = Romberg's sign on heel-to-toe-stalld 
VPT = Vibratioll Perceptioll Threshold 
The numbers of pairs of subsequent scores and measures of fluctuation FOl 
and FlO (see methods) for every sign and symptom in the periods A (during) 
and B (post treatment) are shown in Table 9.3. In period A, we observed high 
values of NO<} and low values of FoI , which implies that scores often remain 
normal during treatment. A change from normal to abnormal was observed 
159 
Chapter 9: Met/JOds for Assessmellt of Chemotherapy-illduced Neuropathy 
most frequently for paraesthesias, sRomberg and ATR. Most of the signs and 
symptoms show little fluctuation (FlO) once they have become abnormal (0.5-
4.2%) with the exception of the sRomberg which shows the highest 
fluctuation in this period (10.5%). In period B, i.e. from the first abnormal 
score post-treatment, the frequency of changes from abnormal to normal 
(F 10) scores are high. Abnormal ATR, knee tendon reflexes (KTR) , 
paraesthesias and sRomberg usually remain abnormal. Once a sign or 
symptom has become normal post-treatment, they remain normal in the 
majority of the cases, which is reflected in low values of F 01 (1.8-7.1%). 
Table 9.4 shows the association between the items of the sum-score. It 
shows that if one item is normal other items are often normal, too. A normal 
score on paraesthesias, sRomberg and ATR are the best predictors for a 
normal score on other items with respectively only lO%, 7% and 8% of the 
other signs or symptoms being abnormal. A normal A TR and sRomberg are 
associated with the lowest mean VPT. An abnormal score on one item often 
goes together with abnormal scores on other items and an increased VPT. 
Abnormal scores for loss of dexterity, unsteadiness of gait, position sense, 
abnormal pin-prick sense and Romberg are the best predictors for an 
abnormal score on other items. Patients with an abnormal pin-prick sense 
show the highest VPT. An abnormal sRomberg is least predictive for 
abnormalities on other items (on average only 32%) and has the lowest 
average VPT. 
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Table 9.3 
The numbers of pairs of subsequent scores and 
measures of fluctuation during treatment (period A). 
Noo No. N" N" Po. Flo (%) (%) 
paraesthesias 246 35 34 10 0.8 3.1 
numbness 306 28 26 9 7.6 2.4 
loss dexterity 360 25 16 4 6.2 1.0 
unsteadiness gait 392 15 6 11 3.5 2.6 
position sense 382 9 3 6 2.3 1.5 
vibration sense 261 30 25 14 9.1 4.2 
pin-prick sense 422 4 1 2 0.9 0.5 
Romberg 414 4 2 4 0.9 0.9 
sRomberg 143 38 57 28 14.3 10.5 
knee tendon 278 28 18 4 8.5 1.2 
reflex 
ankle tendon 164 42 63 9 15.1 3.2 
reflex 
The numbers of pairs of subsequent scores and measures 
of fluctuation post-treatment (period B). 
Noo No. N" N .. Po> p .. 
(%) (%) 
paraesthesias 10 2 80 19 1.8 17.1 
numbness 11 4 43 22 5.0 27.5 
loss dexterity 10 1 24 18 1.9 34.0 
unsteadiness gail 7 2 25 12 4.3 26.1 
position sense 15 4 16 21 7.1 37.5 
vibration sense 17 6 50 37 5.5 33.6 
pin-prick sense 10 2 12 19 4.7 44.2 
Romberg 14 1 12 16 2.3 37.2 
sRomberg 7 7 118 30 4.3 18.5 
knee tendon 5 2 40 11 3.4 19.0 
reflex 
ankle tendon 2 3 70 9 3.6 10.7 
reflex 
Nlj = Humber pairs oj subsequent measurements with i and j equal to a or 1 (0 for nannal and 1 
Jar abnormal) 
FOJ = No/(No,+NQ(J+N1J+NJ(J 
FI" = N,j(NIO+NJ/+N('<)+No/)' 
sRomberg = Rombng's sign with heel-to-toe-stand 
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Table 9.4 
Relation of a normal and abnormal score of one single item with the 
percentage of other abnormal items of the sum-score and vibration 
perception threshold (VPT) in 1050 measurements. 
%abnonnal VPT 
other items 
mean (±SD) mean (±SD) 
paraesthesias nonnal 74% 10 (±13) 0.86 (±O.59) 
abnormal 26% 43 C±22) 1.60 (±1.37) 
numbness normal 82% 12 (±14) 0.90 (±0.63) 
abnonnal18% 52 (±21) 1. 75 (±1.62) 
loss dexterity nonnal 89% 14 (±15) 0.93 (±0.66) 
abnormal 11% 59 (±21) 1.97 (±2.04) 
unsteadiness gait normal 91% 15 C±l7) 0.95 (±0.70) 
abnomlal9% 57 (±24) 1.88 (±1.90) 
position sense nonnal 92% 16 (±18) 0.95 (±0.69) 
abnormal 8% 54 (±25) 2.21 (±2.12) 
vibration sense normal 76% 12 (±15) 0.85 (±O.5S) 
abnormal 24% 41 (±24) 1.76 (±1.61) 
pin-prick sense normal 95% 17 (±19) 0.96 (±O.68) 
abnonnaI 5% 57 (±27) 2.93 (±3.33) 
Romberg nannal 94% 17 (±19) 0.97 (±O. 72J 
abnonnal 6% 50 (±27) 2.04 (±2.04) 
sRolllberg normal 51% 07 (±13) 0.80 (±O.53) 
abnormal 49% 32 (±22) 1.29 (±1.07) 
knee tendon reflex normal 81% 12 (±14) 0.89 (±O.60 
abnormal 19% 54 (±20) 1.87 (±1.63) 
ankle tendon reflex nomlai 62% 08 (±Il) 0.80 (±0.51) 
abnonnal38% 40 (±22) 1.52 (±1.26) 
sRomberg = Romberg's sign with heel-to-toe-stalld 
Table 9.5 shows the percentage of each item that scored abnormal in 
relation to the severity of the neuropathy as expressed by the percentage of 
abnormal items in the sum-score. It shows to what extent one single item 
contributes to the sum-score. For example paraesthesias, vibration sense, 
sRomberg and ATR greatly contribute to an abnormal sum-score at a low 
severity of neuropathy (9-25% of abnormalities in the sum-score). With high 
severity of neuropathy (75%-100% of abnormalities in the sum-score), the 
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items pin-prick sense and Romberg are still scored as normal in a high 
percentage of patients. 
Table 9.5 
The percentage of each item scored abnormal in relation to the severity 
of neuropathy as expressed by the percentage of abnormal items in the 
sum-score. 
abnonnal ahnomlal abnonnal abnormal 
items items items item 
9-25% 25·50% 50·75% 75-100% 
(n::371) (n.:222) (n::83) (n.25) 
paraesthesias 17% 55% 85% 96% 
numbness 5% 33% 83% 96% 
loss de.'i:tcril)' 2% 15% 66% 92% 
unsteadiness gait 3% 13% 43% 88% 
position sense 2% 15% 30% 77% 
vibration sense 18% 49% 66% 100% 
pin-prick sense 2% 8% 20% 65% 
Romberg 4% 10% 19% 60% 
sRomberg 64% 80% 87% 100% 
knee tendon reflex 1% 35% 78% 100% 
ankle tendon reflex 27% 78% 94% 100% 
sRomberg:;: Romberg's sign 011 heel-lo-toe-stancl 
Table 9.6 shows the relation of the CTC grading system for sensory 
neuropathy with the sum-score and the VPT. These findings only relate to a 
subgroup of patients, since the CTC score was introduced at a later time in 
the protocol and was used in docetaxel and cisplatin-docetaxel combination 
trials only. Higher CTC-grades are associated with higher percentages of 
abnormal items and higher mean VPT. There is, however, for all CTC-grades 
a substantial variation in the percentage of abnormal items of the sum-score. 
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Table 9.6 
The common toxicity criteria (CTC) for sensOlY neuropathy in 
relation to the percentage of abnormal items in the sum-score and to 
the vibration perception threshold (VPT). 
eTC-sensory Grade 0 grade 1 gmde2 grade 3 
N observations 437 149 34 11 
% abnormal items 
o % 225 0 0 0 
0-25% 169 27 0 0 
25-50% 43 79 6 2 
50-75 % 0 41 20 
75-100% 0 2 8 8 
mean ±SD 8%±1O 40% ±17 66% ±16 81% ±20 
VPT (mean ±SD) O.76±O.43 1.31 ±O.82 2.61 ±2.49 7.76 ±lO.64 
Discussion 
Chemotherapy-induced peripheral neurotoxicity may influence the 
quality of life of patients with cancer and interfere with an optimal 
treatment. A reliable assessment of neuropathy is thus important for research 
purposes as well as for clinical practice. Ideally, results from clinical studies 
should indicate at what single or cumulative doses significant neuropathy 
\vill emerge. For individual patients, neuropathy assessment tools should 
give a reliable indication of a severe and disabling neuropathy early enough 
for a re-adjustment of the treatment. Several scales have been developed to 
grade chemotherapy-induced neuropathy, but so far no attemps have been 
made to standardize these !-3.'8.14. 
In the assessment of diabetic neuropathy, progress on nerve testing has 
been made by achieving consensus on standardized measurements for 
clinical, morphological, biochemical, electrodiagnostic and quantitative 
sensory testing!'. For assessment of signs and symptoms, Dyck introduced 
different scales by using items from the history for sensory, motor and 
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autonomic nervous system dysfunction"'" and items from the conventional 
neurological examination including scores for cranial nerve, motor and 
sensory deficits", These clinical scales have been validated showing a high 
reproducibility" and a significant association with electrodiagnostic testing, 
VPT and cold detection thresholds"'" as well as with pathological findings in 
nerve biopsies", Such a widely accepted approach on chemotherapy-induced 
neuropathy is lacking, 
The assessment of neurotoxicity has been studied by grading scales for 
clinical signs and symptoms, nerve conduction studies (NCS) and methods 
of quantitative sensory testing (QST), Most of the clinical scales use a 
combination of subjective information from the history together with more 
or less objective findings from the neurological examination mainly focusing 
on sensory signs and symptoms (Table 9,1), 
Conventional NCS have been conducted extensively in cisplatin 
neuropathy, Marked reductions in sensory nerve action potentials (SNAP) 
and mild slowing of sensory nerve conductions velOCity (SNCV) is observed 
once the neuropathy is clinically manifest,,2~19. In paclitaxel neuropathy a 
reduction of SNAP and compound muscle action potentials (CMAP) 
amplitudes have been observed17 • NCS do not seem to be more accurate than 
clinical testing" and the development of clinical symptoms precedes any 
significant change in NCSs,,,. 
A quantitative measurement of the VPT has found to be a reliable 
technique to monitor cisplatin neuropathy. It shows a satifactory correlation 
with the occurrence of signs and symptoms of sensory dysfunction'·J2. In 
docetaxel-induced neuropathy the VPT was poorly associated with the 
severity of the neuropathy". 
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In our neurotoxicity assessment protocol we use a combination of clinical 
scoring and VPT measurement. In the sum-score, we abstract information 
from the histOlY and neurological examination and score several items as 
normal or abnormal. This method has been used before but without 
validationlO • In addition, we use the CTC grading system for sensory 
neuropathy. 
This protocol has now been applied in several prospective trials 
representing large numbers of patients treated with different neurotoxic 
agents. In this report, we present the validation of our method by analysing 
and correlating the biometric findings. The value of this analysis is 
somewhat limited because of the explorative nature and the lack of a golden 
standard for "severity of neuropathy". 
For the validation of the clinical scale, we determined the percentage of 
inconsistent scores for each item. We found a low intra-subject variability in 
normal subjects, except for Romberg's sign in heel-to-toe stand 
(sRomberg)(l1.8%). During and post-treatment, we observed a low level of 
fluctuation in the scoring of most items (0.5-4.2%; sRomberg 10.5%) 
suggesting a high consistency. This was partly due to the fact that most items 
remained normal during treatment. 
We found a low percentage of abnormalities for most items of the clinical 
scale in normal subjects and in cancer patients at the time of the pre-
treatment evaluation. Exceptions were sRomberg, the vibration perception 
sense of the great toe, and the achilles tendon reflex. The higher frequency of 
abnormalities of some items in cancer patients in comparison to normal 
subjects may be partly due to a higher median age in this group, but may 
also reflect "subclinical" neuropathy induced by previous chemotherapy or 
cancer-related neuropathy,,·Jl. As expected during chemotherapy the number 
of abnormal items mid the sum-score increases. Some items become 
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abnormal early in the development of a neuropathy (e.g. paraesthesias, 
sRomberg, ATR), other items at a later stage (e.g. Romberg's sign, pin-prick 
and position sense). None of these items alone would indicate the 
development of a neuropathy. A normal sRomberg, however, is probably a 
sensitive test for ruling out the presence of a sensOlY neuropathy. On the 
other hand, although a positive sRomberg represents a sensitive marker for 
the presence of a sensolY neuropathy, it also represents a highly a-specific 
finding. 
Our clinical scale was clearly related to the CTC score, but there was 
considerable variation in the outcome of the sum-score. Application of our 
sum-score has the advantage over the four graded CTC-scale that it is based 
on more signs and symptoms of neuropathy and would thus provide more 
information on different aspects of neuropathy. Possibly it is also a better 
indicator of the severity of neuropathy, but that has yet to be detennined. 
In the control group we found normal values for the VPT at the hands 
and a clear correlation between age and the VPT comparable to others!"". 
Intra-subject variability was small. The coefficient of variation of the VPT 
was acceptably low. In patients the pretreatment VPT was higher in females 
and this finding may reflect previous chemotherapy \vith cisplatin in some of 
these women. During and after chemotherapy, the VPT was related to values 
of the sum-score and the CTC grade. In an earlier report we have already 
established a strong correlation between the VPT and sum-score in cisplatin 
neuropathy". In docetaxel neuropathy, however, we did not find such a 
reiationshipJ3, which questions the use of this tool in taxoid neurotoxicity 
monitoring. 
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We conclude that our neurotoxicity test-protocol represents a feasible 
method for the assessment of chemotherapy-induced sensory neuropathy on 
a large scale. The limitations of the present analysis preserves us from 
making firm statements concerning the validity of our assessment method. 
The low intra-subject variability of scoring most test-items and the close 
relation between the sum-score and the VPT in cisplatin neuropathy, 
however, suggest that our method is a reliable tool in the assessment of 
sensory nerve dysfunction in clinical trials. 
Further study on the assessment of chemotherapy-induced neuropathy is 
warranted. In addition to the VPT, which primarily is a measure of large 
myelinated fibre function, other QST methods may be explored to detect 
dysfunction of smaller efferent fibres. For the assessment of clinically 
relevant neuropathy in individual patients, grading scales of only signs and 
symptoms are insufficient. The utility of any clinical grading scale depends 
on how this scale relates to the degree of disability, handicap and quality of 
life. This should be subjected to further research. 
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10 Summary and conclusions 
Potential causes of neuropathy associated with cancer include the 
impingement by tumor on a nerve or root, metastases to a nerve, 
leptomeningeal metastases, radiation injury, paraneoplastic neuropathies, 
metabolic disturbances, nutritional deficits and the toxic effects of drugs. 
Peripheral neuropathy induced by anti-neoplastic agents are among the 
many troublesome side-effects encountered in the treatment of cancer. 
Clinical severity may range from some loss of the sensory function and 
paraesthesias to neuropathic pain, severe sensory ataxia or motor weakness 
and may lead to serious disability. The involvement of autonomic nerve 
fibres may cause ileus, orthostatic hypotension, impotence or incontinence 
and may also affect the quality of life. 
Preventing or modifying the neurotoxic side-effects of chemotherapeutic 
agents may thus reduce a potential handicap and disability. The therapeutic 
efficacy may improve as protection of the nerve function may obviate a 
discontinuation of cancer therapy. Better understanding of dosing-schedules 
may prevent or ameliorate neurotoxicity of chemoactive agents. A 
modification of these schedules constitutes one way to prevent nerve 
damage. Preclinical studies on the effects of neuroprotective agents in 
chemotherapy-induced neuropathy have revealed promising results. The 
utilization of these drugs, however, is still experimental. 
In the Daniel den Hoed Cancer Centre many clinical trials on 
chemotherapeutic drugs are performed, testing new schedules or new drugs. 
This setting provides the opportunity for standardized and ongoing 
assessment of neurotoxicity in relatively large groups of patients 
participating in studies testing potentially neurotoxic drugs. A neurotoxicity 
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test-protocol was developed that could be performed quickly and on an out-
patient basis. This test-protocol has been in use since 1990. In this thesis, the 
clinical characteristics and time-course of neurotoxicity induced by a 
number of chemotherapeutical drugs and their assessment with a new test-
protocol are investigated. 
In chapter 1 an overview of the relevant literature on chemotherapy-
induced peripheral neuropathy is presented. Many chemotherapeutic agents 
have occasionally been reported to be neurotoxic, but for only a few of these 
drugs peripheral neuropathy is a clinical significant side-effect. The use of 
high-dose regimens or combination chemotherapy of more than one 
neurotoxic agent has made better insight into the neurotoxic effects of these 
drugs essential. The neurotoxicity of vincristine and cisplatin has been 
extensively investigated and is reviewed here. Emphasis is laid on new and 
promising chemotherapeutic agents in which neuropathy is a prominent 
side-effect, i.e. paclitaxel (Taxol®), docetaxel (Taxotere®) and suramin. The 
degree of neurotoxicity in all these agents is determined by the dose per 
cycle, the cumulative dose or the dose-intensity. Attemps to prevent the 
neurotoxic side-effects of cisplatin by modifying dosing-schedules are 
addressed. The relatively scarce data on the preclinical and clinical use of 
neuroprotective agents are discussed. 
Chapter 2 describes a study on neurotoxicity assessment in 66 patients 
\vith solid cancer treated \vith an intensive weekly regimen of cisplatin 
(cumulative dose: mean 430 mg/m2, range 280-510). A mild to moderate 
neuropathy was found in 71% of the patients and a severe neuropathy in 9%. 
The severity of the neuropathy was strongly related to the cumulative dose of 
cisplatin. Cisplatin-neuropathy progressed after cessation of therapy for a 
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period of approximately three months ("coasting") in many patients. This 
phenomenon makes it difficult to timely stop or re-adjust the schedule in the 
individual patient. The long-term follow-up in this study (12 months) may 
explain the high frequency of neuropathy as compared to observations of 
other investigators. 
The anti-tumor effects of cisplatin are enhanced by intensive dosing 
schedules at the cost of more side-effects. In chapter 3 the effect of dose-
intensity of cisplatin on neurotoxicity is discussed. The literature on this 
issue contains conflicting data. A high dose-intensity has been associated 
\vith both an increase and decrease of neurotoxicity. The patient group from 
the previous chapter is compared with two groups treated \vith cisplatin 
using different dosing-schedules oflower dose-intensity. The analysis 
demonstrates that the severity of the neuropathy expressed as the maximum 
post-treatment vibration perception threshold (VPT) was not related to dose-
intensity but only to cumulative dose. A stronger dose-intensity of cisplatin 
administration \vithin a dose range of 70-100 mg/m' per cycle and a 
cumulative dose range of 280-675 mg/m' does not seem to playa major role 
in the development of neuropathy. The efficacy of cisplatin may thus be 
improved by the use of more intensive dosing schedules \vithout a 
simultaneous risk on increased neurotoxicity. 
In chapter 4 the assessment of peripheral neurotoxicity in 41 patients 
treated with docetaxel is described. Docetaxel is a semi-synthetic analogue of 
paclitaxel and effective in a variety of solid tumors. Peripheral neuropathy is 
one of the potentially dose-limiting side-effects. The cumulative dose these 
patients received varied considerably (150-1100 mg/m'). A predominantly 
sensory neuropathy developed in 20 patients, mainly of mild character. The 
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severity of the neuropathy appeared to be dependent on the cumulative dose. 
At cumulative doses above 600 mg/m2, 3 out of 15 patients developed a 
moderate neuropathy and lout of 15 patients a severe one. Two of these 
patients showed motor involvement. We conclude that neuropathy is not a 
predominant side-effect of docetaxel. However, following treatment with a 
high cumulative dose, some patients may develop a severe, disabling and 
dose-limiting neuropathy. A quantitative measurement of VPT was not or 
weakly associated with the severity of this type of neuropathy. 
In chapter 5 the clinical characteristics and electro diagnostic findings of 
docetaxel-induced peripheral neuropathy are described by presenting case-
reports of five patients who developed a marked neuropathy. Sensory signs 
and symptoms predominate, although in one patient a severe weakness 
developed. We observed progression of the neuropathy after cessation of the 
treatment in three patients. Regression of signs and symptoms occured in 
two patients that could be followed for at least six months. One patient 
developed a prominent sensory neuropathy after only one cycle, suggesting 
individual susceptibility for neurotoxic effects of docetaxel. 
In clwpter 6 five patients are presented who developed Lhermitte's sign 
following the treatment with docetaxel, a phenomenon also seen in cisplatin 
neuropathy. Its mechanism may reflect an abnormal mechano-sensitivity of 
sensory axons at the level of either the roots or dorsal columns following 
dorsal root ganglion damage. This observation supports the hypothesis that 
docetaxel-neuropathy also affects the dorsal root ganglion. 
Chapter 7 involves a study that was performed to determine the effects of 
corticosteroid co-medication on the development of docetaxel-induced 
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neuropathy. Co-medication of corticosteroids is intended to reduce 
docetaxel-induced fluid-retention and hypersensitivity reactions. The patient 
group described in chapter 4 was treated with docetaxel without 
corticosteroid co-medication, since this was not recommended at that time. 
They were compared with a docetaxel-treated group of 49 patients with 
breast cancer who received corticosteroid co-medication routinely. There 
was no statistically significant difference in neurotoxicity between these 
groups, suggesting that corticosteriods do not reduce the development of 
docetaxel-induced neuropathy. 
Chapter 8 describes the neurotoxicity assessment in 63 patients 
participating in a phase I dose-finding trial on a combination chemotherapy 
of docetaxel and cisplatin. Neuropathy developed in 29 out of 55 evaluable 
patients (53%). We compared the results with two other trials in which 
patients received either cisplatin or docetaxel as single agents, presented in 
chapters 2 and 4. The combination of these agents induces a more severe 
neuropathy than either of the two drugs. We Were unable to demonstrate 
whether the drugs have a synergestic neurotoxic effect or which drug mainly 
contributes to the severity of the neuropathy. 
A reliable assessment of the severity of chemotherapy-induced peripheral 
neurotoxicity is relevant for the evaluation of treatment protocols. In 
chapter 9 the neurotoxicity test-protocol that has been developed in the 
Daniel den Hoed Clinic is described. It includes a standard assessment of 
signs and symptoms, the calculation of an ll-point-sum-score, quantitative 
measurements of the vibration perception threshold and grading according 
to the "common toxicity criteria" (CTC). This protocol can be performed 
quickly on an out-patient basis with a minimum of inconvenience for the 
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patient. The validation of this protocol by analysing 944 neurotoxicity 
assessments before, during or after chemotherapy in 298 patients that 
participated in trials on cisplatin and docetaxel and in 55 healthy control 
subjects is discussed. The VPT was statistically significant related to values 
of the sum-score and CTC grade, We found low intra-subject variability for 
the VPT and for most items of the sum-score. This protocol appears to be a 
feasible method for the assessment of chemotherapy-induced neuropathy 
and may serve as a basis for further development of a reliable grading-scale. 
Currently, no effective therapeutic options are available once a patient 
develops a chemotherapy-induced neuropathy. The prevention of 
neurotoxicity by modifying dosing-schedules or the administration of 
neuroprotective agents would have great clinical significance. A better 
understanding of the clinical factors involved in the development of 
chemotherapy-induced neuropathy and the pathophysiological mechanisms 
is needed to find effective means to prevent or treat a dose-limiting 
neurotoxicity. Clinical trials should include a follow-up period long enough 
to observe the progression of the neurotoxicity after cessation of 
chemotherapy. Consensus on the assessment and grading of neurotoxicity 
would facilitate further study. The availability of a neurotoxicity-protocol as 
described in this thesis and the definition of clinical characteristics and time-
course as determined by us are useful to acquire these goals in the near 
future 
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11 Samenvatting en conclusies 
Een perifere neuropathie bij patienten met kanker kan veroorzaakt 
worden door compressie van een tumor op een zenuw of zenuwwortel, 
metastasering naar een zenuw, leptomeningeale metastasering, 
bestralingseffecten, paraneoplastische fenomenen, metabole afwijkingen, 
voedingsdeficienties en de toxische effecten van medicamenten. 
Een door chemotherapie veroorzaakte polyneuropathie is een van de vele 
hinderlijke bijwerkingen van oncologische behandelingen. De ernst hiervan 
varieert sterle Sommige patienten ervaren paraesthesieen of hebben lichte 
sensibele uitval als enig verschijnsel. Anderen worden ernstig gehandicapt 
door het optreden van neuropathische pijn, sensibele ataxie of spierzwakte. 
De kwaliteit van leven kan verdeI' verslechteren door functiestoornissen van 
het autonome zenuwstelselleidend tot orthostatische hypotensie, 
impotentie, incontinentie of ileus. 
Een vennindering van de neurotoxische effecten van cytostatica zou naast 
een afname van bijwerkingen ook gunstig voor de therapeutische effectiviteit 
kunnen zijn: een adequate anti-tumorbehandeling hoeft niet voortijdig te 
worden gestaakt en er kunnen hogere doselingen worden gebruikt. Het 
doseringsschema van de chemotherapie kan van invloed zijn op het ontstaan 
van neurotoxiciteit. Kennis van de factoren die hierbij van belang zijn, kan 
bijdragen tot aanpassingen van deze schema's om zenuwschade zoveel 
mogelijk te beperken. Er zijn veelbelovende publikaties verschenen van pre-
klinische studies over de effecten van neuroprotectieve stoffen op 
chemotherapie-geinduceerde polyneuropathie. De ontwikkeling van deze 
agentia verkeert echter nog in een experimentele fase. 
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In de Daniel den Hoed kliniek worden jaarlijks vele klinische studies 
verricht naar de effectiviteit van nieuwe toedieningsschema's van bestaande 
chemotherapeutica of van nieuwe cytostatica. Dit bood ons de mogelijkheid 
om gestandaardiseerde metingen van neurotoxiciteit te do en in relatief grote 
groepen patienten die met potentieel neurotoxische stoffen werden 
behandeld. Hiertoe werd een neurotoxiciteit testprotocol ontwikkeld dat 
poliklinisch in korte tijd kan worden uitgevoerd en een minimale belasting 
geeft voor de patient. Dit testprotocol is in gebruik sinds 1990. In elit 
proefschrift worden de klinische kenmerken van een aantal door 
chemotherapie veroorzaakte polyneuropathieen beschreven. Daarnaast wordt 
ons testprotocol voor het vaststellen van neurotoxiciteit onderzocht 
C/lOofdstuIl9). 
In llOOfdstll1l1 wordt een overzicht gegeven van de relevante literatuur op 
het gebied van chemotherapie-gelnduceerde polyneuropathie. Bij veel 
chemotherapeutica is het voorkomen van neurotoxiciteit beschreven, maar 
slechts bij enkele van deze agentia wordt een polyneuropathie als een 
klinisch significante bijwerking beschouwd. Het toenemend gebruik van 
chemotherapie met hoge doses of combinaties van neurotoxische cytostatica 
heeft een beter inzicht in de schadelijke effecten van deze medicamenten op 
perifere zenuwen noodzakelijk gemaakt. De neurotoxiciteit van vincristine 
en cisplatin is in het verleden uitgebreid onderzocht en wordt hier 
besproken. De nadruk in dit hoofdstuk wordt echter gelegd op nieuwe, 
veelbelovende cytostatica die polyneuropathie als een belangrijke bijwerking 
hebben, met name paclitaxel (Taxol@), docetaxel (Taxotere@) and suramine. 
De ernst van de neurotoxiciteit van deze middelen wordt bepaald door de 
dosis per kuur, de cumulatieve dosis of de dosis-intensiteit. Pogingen de 
neurotoxische bijwerkingen van cisplatin te voorkomen door het 
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doseringsschema aan te pass en worden besproken. De thans bekende 
gegevens over het gebruik van neuroprotectiva worden uiteengezet. 
Hoofdstu1l2 beschrijft het optreden van neurotoxiciteit bij 66 patienten 
met een solide maligniteit die werden behandeld met cispiatin in een 
intensief doseringsschema (cumulatieve dosis: gemiddeld 430 mg/m2, bereik 
280-510 mg/m'). Een lichte tot matig ernstige polyneuropathie ontwikkelde 
zich bij 71% van de patienten en een ernstige polyneuropathie bij 9%. De 
ernst van de polyneuropathie was sterk gerelateerd aan de cumulatieve dosis 
cisplatin. Bij veel patienten verergerde de cisplatin-polyneuropathie 
gedurende de eerste drie maanden m\ het staken van de therapie. Dit 
fenollleen maakt beslissingen over het tijdig stoppen of aanpassen van de 
dosis in de individuele patient moeilijk. In vergelijking met andere auteurs 
wordt een hoge frequentie van polyneuropathie in deze studie gevonden, 
hetgeen kan worden verklaard door de langdurige follow-up periode (12 
maanden). 
Door het gebruik van meer intensieve doseringsschema's worden de anti-
tumor effecten van cisplatin versterkt ten koste van het optreden van meer 
bijwerkingen. In ltoofdstu1l3 wordt het effect van dosis-intensiteit van 
cisplatin op neurotoxiciteit besproken. De literatuur op dit gebied is niet 
eenduidig. Zowel een toe- als afname van neurotoxiciteit door gebruik van 
een hoge dosis-intensiteit is beschreven. De patientengroep van JlOofdstllJI 2 
wordt vergeleken met twee patientengroepen die behandeld werden met 
doseringsschema's met een lagere dosis-intensiteit. De ernst van de 
polyneuropathie uitgedrukt als de maxilllale vibratie-perceptie-drempel 
(VPT) na de therapie bleek aileen gerelateerd aan de cUlllulatieve dosis en 
niet aan de dosis-intensiteit. Binnen het dosisbereik van deze studie (per 
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kuur: 70-100 mg/m', cumulatief: 280-675 mg/m') lijkt de dosis-intensiteit 
van cisplatin geen belangrijke rol te spelen in het optreden van een 
polyneuropathie. Het gebruik van meer intensieve doseringsschema's ter 
verhoging van de effectiviteit van cisplatin gaat niet gepaard met een 
verhoogd risico op polyneuropathie. 
In Iwojdstlt1l4 wordt de neurotoxiciteit van het perifere zenuwstelsel 
beschreven bij 41 patienten die werden behandeld met docetaxel. Docetaxel 
is een semi-synthetisch analogon van paclitaxel, waarbij gebruik wordt 
gemaakt van een stof die geextraheerd wordt uit de naalden van de Europese 
Taxus Baccata. Docetaxel is effectief gebleken tegen verschillende solide 
tumoren. Een polyneuropathie is een van de potentieJe dosisbeperkende 
bijwerkingen. De bereikte cumulatieve dosis varieerde aanzienlijk tussen 
patienten (150-1100 mg/m'). Er ontwikkelde zich een voornamelijk 
sensibele polyneuropathie in 20 patienten. De ernst van de polyneuropathie 
bleek afhankelijk te zijn van de cumulatieve dosis. Van de 15 patienten die 
een cumulatieve dosis hoger dan 600 mg/m' ontvingen, waren er drie met 
een matig ernstige en een met een ernstige polyneuropathie. Bij twee van 
deze patienten waren er tevens motorische verschijnselen. Polyneuropathie 
is niet een prominente bijwerking van docetaxel in lage dosering. Bij het 
gebruik van een hoge cumulatieve dosis kunnen sommige patienten echter 
een ernstige, invaliderende en dosisbeperkende polyneuropathie 
ontwikkelen. Kwantitatieve metingen van de VPT waren slechts zwak 
geassocieerd met de ernst van polyneuropathie. De VPT is geen geschikte 
kwantitatieve sensibele test voor monitoring van deze vorm van 
polyneuropathie. 
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In hoofdstu11 5 worden de klinische kenmerken en electromyografische 
bevindingen van docetaxel-geinduceerde polyneuropathie beschreven aan de 
hand van vijf ziektegeschiedenissen. Er werden met name sensibele 
symptomen gevonden, echter bij een patient ontstond een ernstige 
spierzwakte. Na het staken van de therapie werd bij drie patienten een 
progressie van de polyneuropathie geconstateerd. Bij de twee patienten die 
tenminste zes maanden konden worden vervolgd, trad er een verbetering op. 
Een patient ontwikkelde een forse sensibele polyneuropathie na slechts een 
kuur, hetgeen een individuele gevoeligheid voor de neurotoxische effecten 
van docetaxel doet vennoeden. 
In hoofdstuh 6 worden vijf patienten gepresenteerd die het teken van 
Lhermitte ontwikkelden na chemotherapie met docetaxel. Dit fenomeen is 
ook bij cisplatin-neuropathie beschreven. Als mechanisme wordt een 
abnormale mechanische gevoeligheid verondersteld van sensibele axonen 
van wortels of achterhoornen na schade aan het dorsale sensibele ganglion. 
Hoofdstu11 7 omvat een prospectieve studie naar de effecten van 
corticosterolden op incidentie en ernst van docetaxel-gelnduceerde 
polyneuropathie. Co-medicatie met corticosterolden wordt momenteel 
gebrnikt tegen het optreden van door docetaxel veroorzaakte vochtretentie 
en overgevoeligheidsreacties. De patientengroep van IlOofdstuh 4 ontving 
geen corticosterolden tijdens chemotherapie met docetaxel, omdat het nut 
daarvan destijds nog niet onderkend was. Deze groep patienten werd 
vergeleken met een groep van 49 patienten met borstkanker die naast 
docetaxel routinematig corticosterolden ontvingen. Er was geen statistisch 
significant verschil in neurotoxiciteit aantoonbaar tussen beide groepen. De 
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ontwikkeling van docetaxel-geindnceerde neuropathie wordt niet beinvloed 
door co-medica tie met corticosteroiden. 
Hoofdstllil 8 beschrijft een prospectieve studie naar de neurotoxiciteit 
veroorzaakt door combinatie chemotherapie met docetaxel en cisplatin. In 
29 van de 55 evalueerbare patienten (53%) werd een voornamelijk sensibele 
polyneuropathie geconstateerd. Bij een cumulatieve dosis boven de 200 
mg/m' van zowel cisplatin als docetaxel ontwikkelden 26 van de 35 
patienten (74%) een neuropathie. Deze was licht bij 15 patienten, matig 
ernstig bij 10 patienten en ernstig bij 1 patient. Deze bevindingen werden 
vergeleken met twee andere trials waarbij patienten werden behandeld met 
cisplatin of docetaxel als enkelvoudige chemotherapie, beschreven in 
respectievelijk IlOofdstll1l2 en 1100fdstllil 4. Combinatie-chemotherapie 
induceert een ernstiger polyneuropathie dan cisplatin of docetaxel in 
vergelijkbare doseringen aileen. Het kon niet worden aangetoond of de 
middelen een synergetisch effect hebben wat hun neurotoxische werking 
betreft en welke van de twee middelen het meest bijdraagt aan de 
neurotoxiciteit. 
Betrouwbare metingen van de ernst van chemotherapie-geinduceerde 
polyneuropathie zijn van belang voor de evaluatie van 
behandelingsprotocollen. In 1100fdstllli 9 komt het neurotoxiciteit 
testprotocol aan de orde dat wordt gebruikt in de Daniel den Hoed ldiniek. 
Dit protocol bevat een gestandaardiseerde anamnese en neurologisch 
onderzoek resulterend in een som-score van 11 punten, kwantitatieve 
metingen van de vibratie perceptie drempel (VPT) en gradering d.m. v. de 
"common toxicity critera" (CTC). Ter validatie van het protocol werden de 
944 neurotoxiciteit metingen v66r, tijdens en na chemotherapie in 298 
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patienten die participeerden in onderzoeken met cisplatin of docetaxel en de 
metingen in 55 gezonde vrijwilligers geanalyseerd. De VPT bleek statistisch 
significant geassocieerd met de som-score en de CTC-gradering. Een lage 
intra-subject variabiliteit voor VPT en voor de meeste items van de som-
score kon worden aangetooud. Dit pratocollijkt een bruikbare methode voor 
het vaststellen van chemotherapie-geinduceerde polyneuropathie en kan 
dienen als een basis voor de verdere ontwikkeling van een graderingsschaal. 
Momenteel bestaan er geen therapeutische opties wanneer een patient 
een chemotherapie gejnduceerde polyneurapathie ontwikkelt. Het 
voorkomen van neurotoxiciteit door modi fica tie van het doseringsschema of 
het gebruik van neuroprotectieve stoffen zou grate klinische consequenties 
hebben. Kennis van Idinische factoren en pathofysiologische mechanismen 
die betrokken zijn bij het ontstaan van een chemotherapie-gejnduceerde 
polyneuropathie is van belang om methoden te ontwikkelen die tot preventie 
of behandeling van neurotoxiciteit kunnen leiden. Bij klinisch onderzoek 
dient de follow-up periode lang genoeg te zijn om progressie van de 
polyneuropathie na het staken van de chemotherapie aan te tonen. 
Consensus over het vaststellen van neurotoxiciteit en gradering van de ernst 
ervan is van belang voor de voortgang van verder onderzoek op dit gebied. 
De beschikbaarheid van klinische kenmerken en het neurotoxiciteit-protocol 
zoals beschreven in dit proefschrift kunnen hieraan een bijdrage leveren. 
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